1
|
Ligeron C, Saenz J, Evrard B, Drouin M, Merieau E, Mary C, Biteau K, Wilhelm E, Batty C, Gauttier V, Baccelli I, Poirier N, Chiffoleau E. CLEC-1 Restrains Acute Inflammatory Response and Recruitment of Neutrophils following Tissue Injury. J Immunol 2024; 212:1178-1187. [PMID: 38353642 DOI: 10.4049/jimmunol.2300479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 01/17/2024] [Indexed: 03/20/2024]
Abstract
The inflammatory response is a key mechanism for the elimination of injurious agents but must be tightly controlled to prevent additional tissue damage and progression to persistent inflammation. C-type lectin receptors expressed mostly by myeloid cells play a crucial role in the regulation of inflammation by recognizing molecular patterns released by injured tissues. We recently showed that the C-type lectin receptor CLEC-1 is able to recognize necrotic cells. However, its role in the acute inflammatory response following tissue damage had not yet been investigated. We show in this study, in a mouse model of liver injury induced by acetaminophen intoxication, that Clec1a deficiency enhances the acute immune response with increased expression of Il1b, Tnfa, and Cxcl2 and higher infiltration of activated neutrophils into the injured organ. Furthermore, we demonstrate that Clec1a deficiency exacerbates tissue damage via CXCL2-dependent neutrophil infiltration. In contrast, we observed that the lack of CLEC-1 limits CCL2 expression and the accumulation, beyond the peak of injury, of monocyte-derived macrophages. Mechanistically, we found that Clec1a-deficient dendritic cells increase the expression of Il1b, Tnfa, and Cxcl2 in response to necrotic cells, but decrease the expression of Ccl2. Interestingly, treatment with an anti-human CLEC-1 antagonist mAb recapitulates the exacerbation of acute immunopathology observed by genetic loss of Clec1a in a preclinical humanized mouse model. To conclude, our results demonstrate that CLEC-1 is a death receptor limiting the acute inflammatory response following injury and represents a therapeutic target to modulate immunity.
Collapse
Affiliation(s)
- Camille Ligeron
- OSE Immunotherapeutics, Nantes, France
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
| | - Javier Saenz
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
| | - Berangere Evrard
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
| | - Marion Drouin
- OSE Immunotherapeutics, Nantes, France
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
| | - Emmanuel Merieau
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
| | | | | | | | | | | | | | | | - Elise Chiffoleau
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
| |
Collapse
|
2
|
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM. The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis. Blood 2024:blood.2023021088. [PMID: 38518105 DOI: 10.1182/blood.2023021088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 03/08/2024] [Accepted: 03/09/2024] [Indexed: 03/24/2024] Open
Abstract
Acute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of precursor B or T cells (BCP- or T-ALL). Current treatment protocols obtain high cure rates in children but are based on toxic polychemotherapy. Novel therapies are urgently needed, especially in relapsed/refractory (r/r) disease, high-risk leukemias and T-ALL, where immunotherapy approaches remain scarce. While the Interleukin-7 receptor (IL-7R) plays a pivotal role in ALL development, no IL-7R-targeting immunotherapy has yet reached clinical application in ALL. The IL-7Rα chain (CD127)-targeting IgG4 antibody Lusvertikimab (formerly OSE-127) is a full antagonist of the IL-7R pathway showing a good safety profile in healthy volunteers. Here, we show that ~85% of ALL cases express surface CD127. We demonstrate significant in vivo efficacy of Lusvertikimab immunotherapy in a heterogeneous cohort of BCP- and T-ALL patient-derived xenografts (PDX) in minimal residual disease (MRD) and overt leukemia models, including r/r and high-risk leukemias. Importantly, Lusvertikimab was particularly effective when combined with polychemotherapy in a phase 2-like PDX study with CD127high samples leading to MRD-negativity in >50% of mice treated with combination therapy. Mechanistically, Lusvertikimab targeted ALL cells via a dual mode of action comprising direct IL-7R antagonistic activity and induction of macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Lusvertikimab-mediated in vitro ADCP levels significantly correlated with CD127 expression levels and the reduction of leukemia burden upon treatment of PDX animals in vivo. Altogether, through its dual mode of action and good safety profile, Lusvertikimab may represent a novel immunotherapy option for any CD127-positive ALL, particularly in combination with standard-of-care polychemotherapy.
Collapse
Affiliation(s)
- Lennart Lenk
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
| | | | - Anna Laqua
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Germany
| | - Julia Heymann
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Germany
| | - Claas Reimer
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
| | - Anna Dietterle
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
| | | | | | | | | | | | | | | | | | - Fotini Vogiatzi
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Kiel, Germany
| | | | | | - Simon Raffel
- Heidelberg University Hospital, Heidelberg, Germany
| | | | - Thomas Schüler
- Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | | | | | - Judith M Boer
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
| | - Wiebke Wessels
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Germany
| | - Matthias Peipp
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Germany
| | - Julia Alten
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Germany
| | - Željko Antić
- Institute of Human Genetics, Medical School Hannover, Hannover, Germany
| | | | - Martin Schrappe
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Germany
| | - Gunnar Cario
- Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany, Germany
| | | | | | - Denis M Schewe
- Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| |
Collapse
|
3
|
Lavy M, Gauttier V, Dumont A, Chocteau F, Deshayes S, Fresquet J, Dehame V, Girault I, Trilleaud C, Neyton S, Mary C, Juin P, Poirier N, Barillé-Nion S, Blanquart C. ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Front Immunol 2023; 14:1196731. [PMID: 37539056 PMCID: PMC10396772 DOI: 10.3389/fimmu.2023.1196731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Accepted: 06/21/2023] [Indexed: 08/05/2023] Open
Abstract
Introduction Tumor Associated Macrophages (TAM) are a major component of the tumor environment and their accumulation often correlates with poor prognosis by contributing to local inflammation, inhibition of anti-tumor immune response and resistance to anticancer treatments. In this study, we thus investigated the anti-cancer therapeutic interest to target ChemR23, a receptor of the resolution of inflammation expressed by macrophages, using an agonist monoclonal antibody, αChemR23. Methods Human GM-CSF, M-CSF and Tumor Associated Macrophage (TAM)-like macrophages were obtained by incubation of monocytes from healthy donors with GM-CSF, M-CSF or tumor cell supernatants (Breast cancer (BC) or malignant pleural mesothelioma (MPM) cells). The effects of αChemR23 on macrophages were studied at the transcriptomic, protein and functional level. Datasets from The Cancer Genome Atlas (TCGA) were used to study CMKLR1 expression, coding for ChemR23, in BC and MPM tumors. In vivo, αChemR23 was evaluated on overall survival, metastasis development and transcriptomic modification of the metastatic niche using a model of resected triple negative breast cancer. Results We show that ChemR23 is expressed at higher levels in M-CSF and tumor cell supernatant differentiated macrophages (TAM-like) than in GM-CSF-differentiated macrophages. ChemR23 activation triggered by αChemR23 deeply modulates M-CSF and TAM-like macrophages including profile of cell surface markers, cytokine secretion, gene mRNA expression and immune functions. The expression of ChemR23 coding gene (CMKLR1) strongly correlates to TAM markers in human BC tumors and MPM and its histological detection in these tumors mainly corresponds to TAM expression. In vivo, treatment with αChemR23 agonist increased mouse survival and decreased metastasis occurrence in a model of triple-negative BC in correlation with modulation of TAM phenotype in the metastatic niche. Conclusion These results open an attractive opportunity to target TAM and the resolution of inflammation pathways through ChemR23 to circumvent TAM pro-tumoral effects.
Collapse
Affiliation(s)
| | | | - Alison Dumont
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
| | - Florian Chocteau
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
| | - Sophie Deshayes
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
| | - Judith Fresquet
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
| | - Virginie Dehame
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
- Nantes Université, CHU Nantes, service de pneumologie, l'institut du thorax, Nantes, France
| | | | | | | | | | - Philippe Juin
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
- ICO René Gauducheau, Saint Herblain, France
| | | | - Sophie Barillé-Nion
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
| | - Christophe Blanquart
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France
| |
Collapse
|
4
|
Poirier N, Baccelli I, Belarif L, Abès R, Teppaz G, Mary C, Poli S, Fromond C, Girault I, Pengam S, Soma E, De Sa F, Conduzorgues JP, Braudeau C, Josien R, Volckaert B, Costantini D, Corallo F. First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα. J Immunol 2023; 210:753-763. [PMID: 36734626 DOI: 10.4049/jimmunol.2200635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 01/11/2023] [Indexed: 02/04/2023]
Abstract
OSE-127 is a humanized mAb targeting the IL-7Rα-chain (CD127), under development for inflammatory and autoimmune disease treatment. It is a strict antagonist of the IL-7R pathway, is not internalized by target cells, and is noncytotoxic. In this work, a first-in-human, phase I, randomized, double-blind, placebo-controlled, single-center study was carried out to determine the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of OSE-127 administration. Sixty-three healthy subjects were randomly assigned to nine groups: six single ascending dose groups with i.v. administration (0.002-10 mg/kg), a single s.c. treatment group (1 mg/kg), and two double i.v. injection groups (6 or 10 mg/kg). Subjects were followed during <146 d. OSE-127's pharmacokinetic half-life after a single dose increased from 4.6 (1 mg/kg) to 11.7 d (10 mg/kg) and, after a second dose, from 12.5 (6 mg/kg) to 16.25 d (10 mg/kg). Receptor occupancy was ≥95% at doses ≥0.02 mg/kg, and this saturation level was maintained >100 d after two i.v. infusions at 10 mg/kg. IL-7 consumption was inhibited by OSE-127 administration, as demonstrated by a decreased IL-7 pathway gene signature in peripheral blood cells and by ex vivo T lymphocyte restimulation experiments. OSE-127 was well tolerated, with no evidence of cytokine-release syndrome and no significant alteration of blood lymphocyte counts or subset populations. Altogether, the observed lack of significant lymphopenia or serious adverse events, concomitant with the dose-dependent inhibition of IL-7 consumption by target cells, highlights that OSE-127 may show clinical activity in IL-7R pathway-involved diseases.
Collapse
Affiliation(s)
| | | | | | - Riad Abès
- OSE Immunotherapeutics, Nantes, France
| | | | | | | | | | | | | | | | | | | | - Cécile Braudeau
- CHU Nantes, Laboratoire d'Immunologie, Centre d'Immunomonitorage Nantes Atlantique, Nantes, France.,CHU Nantes, Nantes Université, INSERM, CR2TI UMR 1064, Nantes, France; and
| | - Regis Josien
- CHU Nantes, Laboratoire d'Immunologie, Centre d'Immunomonitorage Nantes Atlantique, Nantes, France.,CHU Nantes, Nantes Université, INSERM, CR2TI UMR 1064, Nantes, France; and
| | - Bram Volckaert
- SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium
| | | | | |
Collapse
|
5
|
Drouin M, Saenz J, Gauttier V, Evrard B, Teppaz G, Pengam S, Mary C, Desselle A, Thepenier V, Wilhelm E, Merieau E, Ligeron C, Girault I, Lopez MD, Fourgeux C, Sinha D, Baccelli I, Moreau A, Louvet C, Josien R, Poschmann J, Poirier N, Chiffoleau E. CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy. Sci Adv 2022; 8:eabo7621. [PMID: 36399563 PMCID: PMC9674301 DOI: 10.1126/sciadv.abo7621] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Tumors exploit numerous immune checkpoints, including those deployed by myeloid cells to curtail antitumor immunity. Here, we show that the C-type lectin receptor CLEC-1 expressed by myeloid cells senses dead cells killed by programmed necrosis. Moreover, we identified Tripartite Motif Containing 21 (TRIM21) as an endogenous ligand overexpressed in various cancers. We observed that the combination of CLEC-1 blockade with chemotherapy prolonged mouse survival in tumor models. Loss of CLEC-1 reduced the accumulation of immunosuppressive myeloid cells in tumors and invigorated the activation state of dendritic cells (DCs), thereby increasing T cell responses. Mechanistically, we found that the absence of CLEC-1 increased the cross-presentation of dead cell-associated antigens by conventional type-1 DCs. We identified antihuman CLEC-1 antagonist antibodies able to enhance antitumor immunity in CLEC-1 humanized mice. Together, our results demonstrate that CLEC-1 acts as an immune checkpoint in myeloid cells and support CLEC-1 as a novel target for cancer immunotherapy.
Collapse
Affiliation(s)
- Marion Drouin
- OSE Immunotherapeutics, Nantes, France
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | - Javier Saenz
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | | | - Berangere Evrard
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | | | | | | | | | | | | | - Emmanuel Merieau
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | - Camille Ligeron
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | | | - Maria-Dolores Lopez
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | - Cynthia Fourgeux
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | - Debajyoti Sinha
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | | | - Aurelie Moreau
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | - Cedric Louvet
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | - Regis Josien
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
- CHU Nantes, Nantes Université, Laboratoire d’Immunologie, CIMNA, Nantes, France
| | - Jeremie Poschmann
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
| | | | - Elise Chiffoleau
- Nantes Université, INSERM, CHU Nantes, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France
- Corresponding author.
| |
Collapse
|
6
|
De Marco M, Gauttier V, Pengam S, Mary C, Ranieri B, Basile A, Festa M, Falco A, Reppucci F, Cammarota AL, Acernese F, De Laurenzi V, Sala G, Brongo S, Miyasaka M, Shalapour S, Vanhove B, Poirier N, Iaccarino R, Karin M, Turco MC, Rosati A, Marzullo L. Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth. Cell Death Dis 2022; 8:94. [PMID: 35241649 PMCID: PMC8894496 DOI: 10.1038/s41420-022-00817-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 12/09/2021] [Accepted: 01/04/2022] [Indexed: 11/29/2022]
Abstract
The BAG3- and SIRPα- mediated pathways trigger distinct cellular targets and signaling mechanisms in pancreatic cancer microenvironment. To explore their functional connection, we investigated the effects of their combined blockade on cancer growth in orthotopic allografts of pancreatic cancer mt4–2D cells in immunocompetent mice. The anti-BAG3 + anti-SIRPα mAbs treatment inhibited (p = 0.007) tumor growth by about the 70%; also the number of metastatic lesions was decreased, mostly by the effect of the anti-BAG3 mAb. Fibrosis and the expression of the CAF activation marker α-SMA were reduced by about the 30% in animals treated with anti-BAG3 mAb compared to untreated animals, and appeared unaffected by treatment with the anti-SIRPα mAb alone; however, the addition of anti-SIRPα to anti-BAG3 mAb in the combined treatment resulted in a > 60% (p < 0.0001) reduction of the fibrotic area and a 70% (p < 0.0001) inhibition of CAF α-SMA positivity. Dendritic cells (DCs) and CD8+ lymphocytes, hardly detectable in the tumors of untreated animals, were modestly increased by single treatments, while were much more clearly observable (p < 0.0001) in the tumors of the animals subjected to the combined treatment. The effects of BAG3 and SIRPα blockade do not simply reflect the sum of the effects of the single blockades, indicating that the two pathways are connected by regulatory interactions and suggesting, as a proof of principle, the potential therapeutic efficacy of a combined BAG3 and SIRPα blockade in pancreatic cancer.
Collapse
Affiliation(s)
- Margot De Marco
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy.,BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy
| | | | | | | | - Bianca Ranieri
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy
| | - Anna Basile
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy.,BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy
| | - Michela Festa
- BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy.,Department of Pharmacy, University of Salerno, Fisciano, SA, 84084, Italy
| | - Antonia Falco
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy.,BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy
| | - Francesca Reppucci
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy
| | - Anna Lisa Cammarota
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy
| | - Fausto Acernese
- Department of Pharmacy, University of Salerno, Fisciano, SA, 84084, Italy
| | - Vincenzo De Laurenzi
- BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy.,Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" of Chieti-Pescara, 66100, Chieti, Italy
| | - Gianluca Sala
- Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" of Chieti-Pescara, 66100, Chieti, Italy
| | - Sergio Brongo
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy
| | - Masayuki Miyasaka
- Immunology Frontier Research Center, Osaka University, Yamada-oka, Suita, Japan
| | - Shabnam Shalapour
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA
| | | | | | - Roberta Iaccarino
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy
| | - Michael Karin
- Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, USA
| | - Maria Caterina Turco
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy. .,BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy.
| | - Alessandra Rosati
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy.,BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy
| | - Liberato Marzullo
- Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, 84081, Italy.,BIOUNIVERSA s.r.l., R&D Division, Baronissi, SA, 84081, Italy
| |
Collapse
|
7
|
Dehmani S, Nerrière-Daguin V, Néel M, Elain-Duret N, Heslan JM, Belarif L, Mary C, Thepenier V, Biteau K, Poirier N, Blancho G, Haspot F. SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation. Front Immunol 2021; 12:732530. [PMID: 34925315 PMCID: PMC8671138 DOI: 10.3389/fimmu.2021.732530] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Accepted: 10/05/2021] [Indexed: 11/16/2022] Open
Abstract
A numerous number of positive and negative signals via various molecules modulate T-cell activation. Within the various transmembrane proteins, SIRPγ is of interest since it is not expressed in rodents. SIRPγ interaction with CD47 is reevaluated in this study. Indeed, we show that the anti-SIRPγ mAb clone LSB2.20 previously used by others has not been appropriately characterized. We reveal that the anti-SIRPα clone KWAR23 is a Pan anti-SIRP mAb which efficiently blocks SIRPα and SIRPγ interactions with CD47. We show that SIRPγ expression on T cells varies with their differentiation and while being expressed on Tregs, is not implicated in their suppressive functions. SIRPγ spatial reorganization at the immune synapse is independent of its interaction with CD47. In vitro SIRPα-γ/CD47 blockade with KWAR23 impairs IFN-γ secretion by chronically activated T cells. In vivo in a xeno-GvHD model in NSG mice, the SIRPγ/CD47 blockade with the KWAR23 significantly delays the onset of the xeno-GvHD and deeply impairs human chimerism. In conclusion, we have shown that T-cell interaction with CD47 is of importance notably in chronic stimulation.
Collapse
Affiliation(s)
- Safa Dehmani
- OSE Immunotherapeutics, Nantes, France.,Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Véronique Nerrière-Daguin
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Mélanie Néel
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Nathan Elain-Duret
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Jean-Marie Heslan
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | | | | | | | | | | | - Gilles Blancho
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| | - Fabienne Haspot
- Nantes Université, Inserm, Centre de Recherche en Transplantation et Immunologie, Unité Mixte de Recherche (UMR) 1064, Institut de Transplantation Urologie-Néphrologie (ITUN), Nantes, France
| |
Collapse
|
8
|
Gauttier V, Pengam S, Drouin M, Saenz J, Evrard B, Biteau K, Mary C, Teppaz G, Desselle A, Thépénier V, Wilhelm E, Chiffoleau E, Poirier N. Abstract 1636: CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Myeloid cells represent one of the most abundant immune cell types in solid tumors that impede myeloid phagocytosis by triggering “don't eat me” and “don't find me” signals. Recent literature demonstrates that C-type lectin receptors (CLRs) are powerful pattern recognition receptors shaping immune cell-mediated tissue damage by positively or negatively regulating myeloid cell functions and hence tumor elimination or evasion. We previously reported that the orphan CLR CLEC-1 expressed by dendritic cells (DCs) and macrophages (MPs) is enhanced by TGFβ and tempers downstream T cells responses. Furthermore, we observed that CLEC-1 is highly expressed by myeloid cells purified from the human tumor microenvironment, in particular, tumor-associated MPs. We evaluated whether CLEC-1 could also be a receptor for DAMPs and influences phagocytosis. We found that CLEC-1 fusion protein binds specifically to secondary necrotic healthy or tumor cells induced by chemotherapy, radiation (UV, X-ray), or culture stress conditions suggesting that ligands of CLEC-1 are generated upon stress and programmed cell death. Importantly, further to promising results in KO CLEC-1 mice, we observed in vivo that CLEC-1 deficient mice, in contrast to wild-type littermates, eradicate MC38 colorectal tumors in combination with cytotoxic and immunogenic chemotherapy. Importantly, disruption of CLEC-1 signaling by Fc-CLEC-1 fusion protein also promotes tumor eradication. We then generated and identified different anti-human CLEC-1 antagonist monoclonal antibodies (mAbs) with the capacity to block CLEC-1/CLEC-1L interaction. We developed innovative antagonist CLEC-1 mAbs which, in contrast to non-antagonist CLEC-1 control mAb, increase the phagocytosis of CLEC-1L-positive human tumor cells by human TGFβ-polarized DCs or MPs. Indeed, TGFβ-polarized DCs phagocytose more efficiently a NSCLC cell line (A549) as well as Rituximab (anti-CD20 mAb)-opsonized Burkitt lymphoma cells (Raji) when CLEC-1 is antagonized by Abs. Similarly, macrophages significantly more efficiently engulfed human tumors in the presence of CLEC-1 antagonist Abs, in particular when tumor cells were opsonized such as Rituximab-opsonized Raji cells, Cetuximab opsonized colon carcinoma cells (DLD-1; EGFR+) or Trastuzumab opsonized mammary carcinoma cells (SK-BR-3; Her2+). Importantly, we observed both in vitro and in vivo that DCs from Clec1a deficient mice cross-present more efficiently dead cell-associated antigens to CD8+ T cells (OT-1). We generated hCLEC-1 knock-in mice and in vivo preclinical evaluation of CLEC-1 blocking mAbs is ongoing. Altogether, these data illustrate that CLEC-1 broadly notably inhibits tumor-cell phagocytosis and synergized with tumor-targeted cytotoxic monoclonal antibodies in both solid and hematological tumors, and hampers DC antigen cross-presentation.
Citation Format: Vanessa Gauttier, Sabrina Pengam, Marion Drouin, Javier Saenz, Bérangère Evrard, Kevin Biteau, Caroline Mary, Géraldine Teppaz, Ariane Desselle, Virginie Thépénier, Emmanuelle Wilhelm, Elise Chiffoleau, Nicolas Poirier. CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1636.
Collapse
|
9
|
Gauttier V, Lavy M, Trilleaud C, Biteau K, Girault I, Belarif L, Teppaz G, Mary C, Thépénier V, Blanquart C, Barillé-Nion S, Poirier N. Abstract 1766: Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-1766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Chronic inflammation is associated with abnormal non-phlogistic clearance (efferocytosis) of apoptotic cells by macrophages and a defect of the resolution of inflammation pathways. The resolution of inflammation is an active immunological process mediated by specialized pro-resolving mediator (SPM) which target specific resolutive G-protein coupled receptors expressed by different immune cells and participate to the tissue homeostasis return after an injury. Defects in the clearance of (chemotherapy-induced) apoptotic tumor cell debris strengthens inflammation and has been associated with exacerbated tumor growth in several preclinical models. Proresolutive therapeutic approaches, such as using exogenous resolvin E1 (RvE1), the natural lipidic proresolutive ligand of the GPCR ChemR23, have been shown to dampen tumor-associated inflammation and to reduce tumor growth. Using single-cell RNA sequencing analysis, we found that ChemR23 is mainly expressed by tumor-associated macrophages in melanoma and lung cancers. Moreover, ChemR23 expression was barely expressed in non-inflamed tissues indicating a preferential expression on the inflamed or tumor site. We screened and identified an anti-ChemR23 mAb which induces RvE1-like Akt and ERK signaling in mouse and human macrophages and favors macrophage polarization towards a pro-resolutive phenotype. In vitro, the agonist antibody significantly increased the phagocytosis of apoptotic tumor primary mesothelioma cells by human tumor-polarized macrophages. In vivo, the agonist ChemR23 mAb accelerates the resolution of inflammation in an acute inflammatory model, as illustrated by a significant decrease of inflammatory macrophages and neutrophils infiltrates as compared to isotype control groups both in mice and non-human primate models. Similarly, ChemR23 triggering with the anti-ChemR23 mAb improved weight recovery, reduced diarrhea and decreased the development of colon neoplastic foci in a chronic colitis model coupled with the injection of a carcinogen agent. Furthermore, the administration of the anti-ChemR23 mAb as a monotherapy displayed some partial and complete antitumor responses in immunocompetent mouse models of subcutaneous colon carcinoma (MC38 and CT26) as well as orthotopic mesothelioma (AK7). Finally, using an orthotopic triple-negative breast cancer model (4T1), while we observed a limited impact on primary tumor growth, spontaneous metastasis development in the lung was significantly inhibited by the ChemR23 agonist mAb monotherapy. Our study reveals for the first time the therapeutic potential of triggering the proresolutive pathways using an anti-ChemR23 agonistic mAb to limit chronic inflammation in the tumor microenvironment and inhibit metastasis development.
Citation Format: Vanessa Gauttier, Margot Lavy, Charlène Trilleaud, Kévin Biteau, Isabelle Girault, Lyssia Belarif, Géraldine Teppaz, Caroline Mary, Virginie Thépénier, Christophe Blanquart, Sophie Barillé-Nion, Nicolas Poirier. Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1766.
Collapse
|
10
|
Morello A, Durand J, Seite M, Thepenier V, Teppaz G, Wilhelm E, Desselle A, Mary C, Poirier N. Abstract 692: Optimized antagonist anti-PD-1/IL-7 bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Although anti PD(L)-1 therapy lead to impressive responses, the majority of patient are unresponsive or fail to develop a durable response after treatment. Immunocytokines have the potential to strengthen PD-(L)1 therapy by promoting T cell survival, however, their clinical developments are limited by a shortened half-life and systemic toxicity. To redirect immunotherapy to tumor specific T cells, we propose to selectively deliver IL-7 to PD1+ T cells using a bispecific anti-PD1 fused to IL-7 (BiCKI®IL-7). Intratumoral progenitor exhausted CD8+ T cells (Tpex) coexpressing PD1/IL-7R+ were described as the key subset responsive to anti PD-(L)1; but their efficacies are transient as Tpex rapidly undergo apoptosis limiting the full efficacy of anti-PD-(L)1. BICKI®IL7 was specifically designed to preferentially reinvigorate effector functions of PD1+IL-7R+ tumor-specific T cells, to sustain long-term anti-tumor response and counteract immune resistance in refractory patients.
BICKI®IL7 was created by the fusion of a flexible linker and human IL-7 to the Fc portion of a high affinity antagonist anti-PD1 antibody. BICKI®IL7 constructed with wild-type IL-7 exhibited a high binding and potency (pSTAT5 IL-7 signaling) irrespective of PD1 expression. As our goal is to selectively activate the IL-7 signaling into PD1+ T cells but not PD1 negative cells, we fused different IL-7 muteins having 2 to 30,000-fold lower affinity for CD127/CD132 complex. One BICKI®IL7 mutein construction was selected for its loss of potency on PD1- cells and its optimal cis-binding/redirection and cis-activity on PD1+ cells. Furthermore, BICKI®IL7 mutein fully antagonized the PD-L1/2 interactions and inhibitory signaling to a similar extent to the naked anti PD1. Interestingly, BICKI®IL7 mutein synergistically activates TCR signaling while IL-7+anti-PD1 combo has no additive effect. Using a chronic antigen stimulation model, we demonstrated that BICKI®IL-7 efficiently activates and sustains the proliferation of early and fully exhausted T cells, and also confirmed the synergy. In parallel, we also explored the effect of the BICKI®IL7 mutein on Tregs in coculture assay. BICKI®IL7 mutein preferentially stimulated CD8 Teff over Treg as opposed to IL-2 & IL-15 and, also abrogated Treg suppression by restoring Teff IFN-γ secretion and proliferation. In vivo, BICKI®IL-7 mutein enhanced anti-tumor responses in mesothelioma model and promoted the proliferation and generation of memory CD8 T cells to higher extent to anti-PD1 treatment. Taken together, our data validate the therapeutic potential of providing IL-7 signal to strengthen PD1 therapy and prevent immunoresistance by sustaining T cell response and overcoming Treg suppression. The bispecific BiCKI®IL-7 mutein can preferentially deliver and activate IL-7 into PD1+ tumor-specific T cells limiting the risk of I-O/I-O immunotoxicity.
Citation Format: Aurore Morello, Justine Durand, Margaux Seite, Virginie Thepenier, Géraldine Teppaz, Emmanuelle Wilhelm, Arianne Desselle, Caroline Mary, Nicolas Poirier. Optimized antagonist anti-PD-1/IL-7 bispecific antibody to sustain exhausted T cell function and to disarm Treg suppressive activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 692.
Collapse
|
11
|
Trilleaud C, Gauttier V, Biteau K, Girault I, Belarif L, Mary C, Pengam S, Teppaz G, Thepenier V, Danger R, Robert-Siegwald G, Néel M, Bruneau S, Glémain A, Néel A, Poupon A, Mosnier JF, Chêne G, Dubourdeau M, Blancho G, Vanhove B, Poirier N. Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. Sci Adv 2021; 7:eabd1453. [PMID: 33811066 PMCID: PMC11057782 DOI: 10.1126/sciadv.abd1453] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 02/16/2021] [Indexed: 06/12/2023]
Abstract
Resolution of inflammation is elicited by proresolving lipids, which activate GPCRs to induce neutrophil apoptosis, reduce neutrophil tissue recruitment, and promote macrophage efferocytosis. Transcriptional analyses in up to 300 patients with Inflammatory Bowel Disease (IBD) identified potential therapeutic targets mediating chronic inflammation. We found that ChemR23, a GPCR targeted by resolvin E1, is overexpressed in inflamed colon tissues of severe IBD patients unresponsive to anti-TNFα or anti-α4β7 therapies and associated with significant mucosal neutrophil accumulation. We also identified an anti-ChemR23 agonist antibody that induces receptor signaling, promotes macrophage efferocytosis, and reduces neutrophil apoptosis at the site of inflammation. This ChemR23 mAb accelerated acute inflammation resolution and triggered resolution in ongoing chronic colitis models, with a significant decrease in tissue lesions, fibrosis and inflammation-driven tumors. Our findings suggest that failure of current IBD therapies may be associated with neutrophil infiltration and that ChemR23 is a promising therapeutic target for chronic inflammation.
Collapse
Affiliation(s)
- C Trilleaud
- OSE Immunotherapeutics, Nantes, France
- Université de Nantes
| | | | - K Biteau
- OSE Immunotherapeutics, Nantes, France
| | - I Girault
- OSE Immunotherapeutics, Nantes, France
| | - L Belarif
- OSE Immunotherapeutics, Nantes, France
| | - C Mary
- OSE Immunotherapeutics, Nantes, France
| | - S Pengam
- OSE Immunotherapeutics, Nantes, France
| | - G Teppaz
- OSE Immunotherapeutics, Nantes, France
| | | | - R Danger
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- [ITUN], 44000 Nantes, France
| | | | - M Néel
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- [ITUN], 44000 Nantes, France
| | - S Bruneau
- Université de Nantes
- [ITUN], 44000 Nantes, France
| | - A Glémain
- Université de Nantes
- [ITUN], 44000 Nantes, France
| | - A Néel
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- Service de Médecine Interne, CHU de Nantes, Nantes, France
| | | | - J F Mosnier
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- Service d'Anatomie et Cytologie Pathologiques, CHU Nantes, Nantes, France
| | - G Chêne
- Ambiotis, Canal Biotech 2, Toulouse, France
| | | | - G Blancho
- Université de Nantes
- [CHU Nantes], INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064
- [ITUN], 44000 Nantes, France
| | - B Vanhove
- OSE Immunotherapeutics, Nantes, France
| | - N Poirier
- OSE Immunotherapeutics, Nantes, France.
| |
Collapse
|
12
|
Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Ralph K, Trombetta ES, Garcia A, Vignard V, Martinet B, Glémain A, Bruneau S, Haspot F, Dehmani S, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest 2021; 130:6109-6123. [PMID: 33074246 DOI: 10.1172/jci135528] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 08/06/2020] [Indexed: 12/12/2022] Open
Abstract
T cell exclusion causes resistance to cancer immunotherapies via immune checkpoint blockade (ICB). Myeloid cells contribute to resistance by expressing signal regulatory protein-α (SIRPα), an inhibitory membrane receptor that interacts with ubiquitous receptor CD47 to control macrophage phagocytosis in the tumor microenvironment. Although CD47/SIRPα-targeting drugs have been assessed in preclinical models, the therapeutic benefit of selectively blocking SIRPα, and not SIRPγ/CD47, in humans remains unknown. We report a potent synergy between selective SIRPα blockade and ICB in increasing memory T cell responses and reverting exclusion in syngeneic and orthotopic tumor models. Selective SIRPα blockade stimulated tumor nest T cell recruitment by restoring murine and human macrophage chemokine secretion and increased anti-tumor T cell responses by promoting tumor-antigen crosspresentation by dendritic cells. However, nonselective SIRPα/SIRPγ blockade targeting CD47 impaired human T cell activation, proliferation, and endothelial transmigration. Selective SIRPα inhibition opens an attractive avenue to overcoming ICB resistance in patients with elevated myeloid cell infiltration in solid tumors.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Mélanie Néel
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Georgia Porto
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | | | | | - Richard Danger
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Nicolas Vince
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | | | | | - Riad Abes
- OSE Immunotherapeutics, Nantes, France
| | | | - Charlène Trilleaud
- OSE Immunotherapeutics, Nantes, France.,Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Kerry Ralph
- Cancer Immunology & Immune Modulation, Boehringer Ingelheim, Ridgefield, Connecticut, USA
| | - E Sergio Trombetta
- Cancer Immunology & Immune Modulation, Boehringer Ingelheim, Ridgefield, Connecticut, USA
| | - Alexandra Garcia
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Virginie Vignard
- CHU Nantes, Nantes, France.,Université de Nantes, CNRS, INSERM, Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), F-44000 Nantes, France
| | - Bernard Martinet
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Alexandre Glémain
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Sarah Bruneau
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Fabienne Haspot
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Safa Dehmani
- OSE Immunotherapeutics, Nantes, France.,Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Pierre Duplouye
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Masayuki Miyasaka
- Immunology Frontier Research Center, Osaka University, Yamada-oka, Suita, Japan
| | - Nathalie Labarrière
- Université de Nantes, CNRS, INSERM, Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), F-44000 Nantes, France
| | - David Laplaud
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Stéphanie Le Bas-Bernardet
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Christophe Blanquart
- Université de Nantes, CNRS, INSERM, Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), F-44000 Nantes, France
| | - Véronique Catros
- Université de Rennes, INSERM, CHU Rennes, Institut NUMECAN (Nutrition Metabolisms and Cancer), UMR_S 1241, CRB Santé Rennes, Rennes, France
| | - Pierre-Antoine Gouraud
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | - Isabelle Archambeaud
- CHU Nantes, Nantes, France.,Institut des Maladies de l'Appareil Digestif (IMAD), Service d'Hépato-Gastro-Entérologie et Chirurgie Digestive
| | - Hélène Aublé
- CHU Nantes, Nantes, France.,Institut des Maladies de l'Appareil Digestif (IMAD), Service d'Hépato-Gastro-Entérologie et Chirurgie Digestive.,Centre d'investigation Clinique and
| | - Sylvie Metairie
- CHU Nantes, Nantes, France.,Institut des Maladies de l'Appareil Digestif (IMAD), Service d'Hépato-Gastro-Entérologie et Chirurgie Digestive
| | - Jean-François Mosnier
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,Service d'Anatomie et Cytologie Pathologiques, CHU Nantes, Nantes, France
| | | | - Gilles Blancho
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France.,CHU Nantes, Nantes, France
| | - Sophie Conchon
- Université de Nantes, INSERM, Centre de Recherche en Transplantation et Immunologie, UMR 1064.,Institut de Transplantation Urologie Néphrologie (ITUN), F-44000 Nantes, France
| | | | | |
Collapse
|
13
|
Mary C, Morello A, Thepenier V, Teppaz G, Durand J, Poirier N. Abstract 2287: Bispecific anti-PD1 checkpoint inhibitors antibodies (BiCKI), an optimized platform designed to tackle anti-PD-(L)1 primary and secondary resistance mechanisms. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-2287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Although Anti PD(L)1 therapy lead to impressive therapeutic responses by reinvigorating T cells, primary and secondary resistances occur de novo or during treatment impeding the full efficacy of the drug. To tackle this resistance mechanisms and reduced the immunotoxicity of combination therapy, we designed a 2nd generation of anti-PD1 antibody by fusing immune protein to the Fc portion of the antibody, named BiCKI®. The anti PD1 will more selectively drive the immune active drug on antigen-experienced (PD1+) T cells, through cis-targeting mechanism. These bifunctional molecules were designed with an optimized anti-PD1 backbone for bispecific format, fused to an active protein domain to the C-ter of heavy and/or light chains. Different protein candidate were successfully fused to the optimized anti-PD1, such as cytokines, costimulatory molecules, or dominant negative receptors with PD1/PDL1 full antagonistic activity. In contrast to combination, BiCKI® antibodies enable the simultaneous dual-binding specificity in a single drug allowing a synergistic activation. Each BiCKI® is selected on its synergistic capacity to re-activate of anti-tumor T cell responses or TCR signaling in cell-based assays. Bispecific antibody development in clinic has been hampered by difficult manufacturing process, reduced pharmacokinetic (PK) and drug exposure. Both anti PD-1 CDRs and VH/VL framework sequences were carefully selected and optimized for bioproductivity and biostability of the molecule. A 2 to 15-fold increased productivity in mammalian cells was observed versus the non-optimized anti-PD1 antibody or other anti-PD-1 bispecific backbones as Pembrolizumab or Nivolumab. We also evaluated the impact of the Fc isotype,linker flexibility and affinity of the fused compound on the PK profile of different bispecifics fused to costimulatory molecules or cytokines. The IgG isotype with reduced FcgR binding property, of the anti-PD-1 backbone was associated with a better PK profile with some exceptions for cytokine. The presence or length of a linker between Fc domain and the fused protein has a small impact the PK and drug efficacy. More importantly, the affinity of the fused compound has an impact the PK profile of BiCKI® For example, the anti-PD-1 fused to wild-type IL-7 cytokine possesses a high affinity for the CD127/CD132 receptors but display a reduced drug exposure both in mouse and cynomolgus. This potential difficulty was solved with further improved products including IL-7 mutants having reduced affinity for CD127 and/or CD132. While significant correlation between IL7 affinity and PK has been observed, increased PK and drug exposure could be achieved using optimized combination of Fc isotype a linker length design and BiCKI-IL7 mutants retaining significant IL7R signaling. Conclusion: Our BICKI® platform was designed to overcome major hurdles of bispecific antibody development, we improved its manufacturability and drug exposure by selectively designing the structure of bispecific antibodies. By fusing costimulatory molecule, cytokines or dominant negative receptor to the anti PD-1 blocking antibody, we can generate and select various efficient bispecific molecules acting in synergy to counteract primary and secondary resistance mechanisms of anti-PD(L)1 therapies.
Citation Format: Caroline Mary, Aurore Morello, Virginie Thepenier, Géraldine Teppaz, Justine Durand, Nicolas Poirier. Bispecific anti-PD1 checkpoint inhibitors antibodies (BiCKI), an optimized platform designed to tackle anti-PD-(L)1 primary and secondary resistance mechanisms [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2287.
Collapse
|
14
|
Morello A, Durand J, Thepenier V, Teppaz G, Seite M, Pengam S, Mary C, Poirier N. Abstract 910: A novel bifunctional anti-PD-1 IL-7 fusion protein to reinvigorate exhausted T cell and disarms Treg suppressive activity. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-910] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite the clinical success of anti-PD(L)1 therapy, the majority of patient remain unresponsive or fail to develop a durable response. We explored a second generation of PD-1 antibody by fusing IL-7 cytokine to the Fc portion, called BiCKI® IL-7. The high affinity of the anti PD-1 antibody will allow the concentration/retention of the drug into the tumor microenvironment and preferentially deliver IL-7 in cis-dependent manner to PD-1+ cells. IL-7 is an optimal target for immunotherapy to preferentially stimulate effector T-cell (Teff) functions over regulatory T-cells (Treg)due to the differential expression of IL-7R and poor capacity of IL-7 to stimulate Treg proliferation. Moreover, It has been published that PD-1 blockades increase IL-7R expression and improve IL-7 signaling in exhausted T-cells rationalizing our combinatorial approach.
Results Our anti PD-1/IL-7 bispecific antibody efficiently blocks the PD-1/PD-L1 and PD-L2 interactions and the PD-1-mediated inhibitory signal (pSHP1) and in parallel activates IL-7R pSTAT5 signaling into T cells. Anti PD-1/IL-7 preferentially binds in cis to T cells coexpressing PD-1 and CD127 enabling a selective activation of primed antigen- experienced T cells over PD1-negative (e.g. naïve) cells. A high affinity/avidity of the molecule was observed using biosensor when both receptor CD127 and PD-1, supporting the cis-targeting activity of the drug. Using in vitro T cell activation bioassay, we observed that IL-7 portion fused to the anti-PD-1 synergizes to enhance TCR mediated signaling (NFAT) through activation of the non-canonical pathway while IL-7 in combination with anti-PD1 (two separates product) has no additive effect. Although IL-7R expression decrease over chronic stimulation of Teff cells, we demonstrated that IL-7 efficiently activates progenitor and some fully-exhausted human T-cells (pSTAT5) and maintain their proliferation and survival capacity. This IL-7R signaling activation was associated with a significant increased IFNγ secretion using ex-vivo fresh human tumor explant culture. A significant higher IFNγ production was obtained with anti PD-1/IL-7compared to anti PD-1 treatment alone, including in non-responder patients to anti-PD1, suggesting that the anti PD-1/IL-7 bispecific can reactivate TILs that are resistant to PD-1 therapy. Knowing that Tregs have a key suppressive function, we also explored the possibility that anti-PD-1/IL-7 affect Treg functions. In a human Treg/Teff coculture assay, anti PD-1/IL-7 abrogates the Treg capacity to inhibit proliferation and IFN-g secretion of CD8+ Teff. Moreover, IL-7 and anti-PD-1/IL-7 does not stimulate Treg proliferation, in contrast to IL-2 and IL-15.
Conclusion Our data validate the therapeutic potential of providing IL-7 signals to overcome PD-1 resistance. The bifunctional anti-PD1/IL-7 favors the T-cell effector over T-regulatory immune balance by stimulating Teff cells and exhausted T-cell, while disarming Tregs suppressive functions.
Citation Format: Aurore Morello, Justine Durand, Virginie Thepenier, Géraldine Teppaz, Margaux Seite, Sabrina Pengam, Caroline Mary, Nicolas Poirier. A novel bifunctional anti-PD-1 IL-7 fusion protein to reinvigorate exhausted T cell and disarms Treg suppressive activity [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 910.
Collapse
|
15
|
Mai HL, Nguyen TVH, Branchereau J, Poirier N, Renaudin K, Mary C, Belarif L, Minault D, Hervouet J, Le Bas-Berdardet S, Soulillou JP, Vanhove B, Blancho G, Brouard S. Interleukin-7 receptor blockade by an anti-CD127 monoclonal antibody in nonhuman primate kidney transplantation. Am J Transplant 2020; 20:101-111. [PMID: 31344323 DOI: 10.1111/ajt.15543] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 06/28/2019] [Accepted: 07/19/2019] [Indexed: 01/25/2023]
Abstract
IL-7 is an important cytokine for T cell lymphopoiesis. Blockade of the IL-7 signaling pathway has been shown to induce long-term graft survival or graft tolerance in murine transplant models through inhibiting T cell homeostasis and favoring immunoregulation. In this study, we assessed for the first time the effects of a blocking anti-human cluster of differentiation 127 (CD127) mAb administered in combination with low-dose tacrolimus or thymoglobulin in a life-sustaining kidney allograft model in baboons. Contrary to our expectation, the addition of an anti-CD127 mAb to the treatment protocols did not prolong graft survival compared to low-dose tacrolimus alone or thymoglobulin alone. Anti-CD127 mAb administration led to full CD127 receptor occupancy during the follow-up period. However, all treated animals lost their kidney graft between 1 week and 2 weeks after transplantation. Unlike in rodents, in nonhuman primates, anti-CD127 mAb treatment does not decrease the absolute numbers of lymphocyte and lymphocyte subsets and does not effectively inhibit postdepletional T cell proliferation and homeostasis, suggesting that IL-7 is not a limiting factor for T cell homeostasis in primates.
Collapse
Affiliation(s)
- Hoa Le Mai
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Thi Van Ha Nguyen
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Julien Branchereau
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.,Service d'Urologie, CHU Nantes, France
| | | | - Karine Renaudin
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.,Service d'Anatomie et Cytologie Pathologiques, CHU Nantes, France
| | | | | | - David Minault
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Jeremy Hervouet
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Stéphanie Le Bas-Berdardet
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Jean-Paul Soulillou
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | | | - Gilles Blancho
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Sophie Brouard
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| |
Collapse
|
16
|
Delaunay P, Hérisé A, Hasseine L, Chiaverini C, Tran A, Mary C, Del Giudice P, Marty P, Akhoundi M, Hubiche T. Testing a possible new way to diagnose scabies. Br J Dermatol 2020. [DOI: 10.1111/bjd.18663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Delaunay P, Hérisé A, Hasseine L, Chiaverini C, Tran A, Mary C, Del Giudice P, Marty P, Akhoundi M, Hubiche T. 测试一种可能的新的疥疮诊断方法. Br J Dermatol 2020. [DOI: 10.1111/bjd.18680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Pengam S, Durand J, Usal C, Gauttier V, Dilek N, Martinet B, Daguin V, Mary C, Thepenier V, Teppaz G, Renaudin K, Blancho G, Vanhove B, Poirier N. SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells. Am J Transplant 2019; 19:3263-3275. [PMID: 31207067 DOI: 10.1111/ajt.15497] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Revised: 05/12/2019] [Accepted: 05/30/2019] [Indexed: 01/25/2023]
Abstract
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature hematopoietic precursors known to suppress immune responses. Interaction of SIRP alpha (SIRPα), expressed by myeloid cells, with the ubiquitous receptor CD47 is an important immune checkpoint of the innate response regulating macrophages and dendritic cells functions. We previously described that MDSC expressing SIRPα accumulated after transplantation and maintained kidney allograft tolerance. However, the role of the SIRPα/CD47 axis on MDSC function remained unknown. Here, we found that blocking SIRPα or CD47 with monoclonal antibodies (mAbs) induced differentiation of MDSC into myeloid cells overexpressing MHC class II, CD86 costimulatory molecule and increased secretion of macrophage-recruiting chemokines (eg, MCP-1). Using a model of long-term kidney allograft tolerance sustained by MDSC, we observed that administration of blocking anti-SIRPα or CD47 mAbs induced graft dysfunction and rejection. Loss of tolerance came along with significant decrease of MDSC and increase in MCP-1 concentration in the periphery. Graft histological and transcriptomic analyses revealed an inflammatory (M1) macrophagic signature at rejection associated with overexpression of MCP-1 mRNA and protein in the graft. These findings indicate that the SIRPα-CD47 axis regulates the immature phenotype and chemokine secretion of MDSC and contributes to the induction and the active maintenance of peripheral acquired immune tolerance.
Collapse
Affiliation(s)
| | - Justine Durand
- OSE Immunotherapeutics, Nantes, France.,Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France
| | - Claire Usal
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France
| | | | - Nahzli Dilek
- OSE Immunotherapeutics, Nantes, France.,Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France
| | - Bernard Martinet
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France
| | - Véronique Daguin
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France
| | | | | | | | - Karine Renaudin
- Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | - Gilles Blancho
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France
| | | | | |
Collapse
|
19
|
Delaunay P, Hérissé A, Hasseine L, Chiaverini C, Tran A, Mary C, Del Giudice P, Marty P, Akhoundi M, Hubiche T. Scabies polymerase chain reaction with standardized dry swab sampling: an easy tool for cluster diagnosis of human scabies. Br J Dermatol 2019; 182:197-201. [DOI: 10.1111/bjd.18017] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/16/2019] [Indexed: 11/27/2022]
Affiliation(s)
- P. Delaunay
- Parasitologie‐Mycologie Hôpital de l'Archet Centre Hospitalier Universitaire de Nice Nice France
- MIVEGEC UMR IRD 224‐CNRS 5290‐Université de Montpellier Montpellier France
| | - A.L. Hérissé
- Parasitologie‐Mycologie Hôpital de l'Archet Centre Hospitalier Universitaire de Nice Nice France
- Urgences Pédiatriques Centre Hospitalier Universitaire Hôpital Pédiatrique Lenval Nice France
| | - L. Hasseine
- Parasitologie‐Mycologie Hôpital de l'Archet Centre Hospitalier Universitaire de Nice Nice France
| | - C. Chiaverini
- Dermatologie Hôpital de l'Archet Centre Hospitalier Universitaire de Nice Nice France
| | - A. Tran
- Urgences Pédiatriques Centre Hospitalier Universitaire Hôpital Pédiatrique Lenval Nice France
| | - C. Mary
- Parasitologie‐Mycologie Assistance Publique des Hôpitaux de Marseille Hôpital de La Timone Marseille France
| | | | - P. Marty
- Parasitologie‐Mycologie Hôpital de l'Archet Centre Hospitalier Universitaire de Nice Nice France
- Inserm U1065 Centre Méditerranéen de Médecine Moléculaire Université Nice‐Sophia Antipolis Nice France
| | - M. Akhoundi
- Parasitologie‐Mycologie Hôpital de l'Archet Centre Hospitalier Universitaire de Nice Nice France
- MIVEGEC UMR IRD 224‐CNRS 5290‐Université de Montpellier Montpellier France
| | - T. Hubiche
- Dermatologie Hôpital de l'Archet Centre Hospitalier Universitaire de Nice Nice France
- Infectiologie‐Dermatologie Hôpital Bonnet Fréjus France
| |
Collapse
|
20
|
Luke NB, Emily BL, Suzanne EJ, Madeline RS, Parag G, Mary C, Monika MS, Orlando MG. Correction. JACC Heart Fail 2019; 7:636. [PMID: 31248577 PMCID: PMC6625520 DOI: 10.1016/j.jchf.2019.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
|
21
|
Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NSL, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, MacDonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019; 129:1910-1925. [PMID: 30939120 DOI: 10.1172/jci121668] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 02/21/2019] [Indexed: 12/16/2022] Open
Abstract
It remains unknown what causes inflammatory bowel disease (IBD), including signaling networks perpetuating chronic gastrointestinal inflammation in Crohn's disease (CD) and ulcerative colitis (UC), in humans. According to an analysis of up to 500 patients with IBD and 100 controls, we report that key transcripts of the IL-7 receptor (IL-7R) pathway are accumulated in inflamed colon tissues of severe CD and UC patients not responding to either immunosuppressive/corticosteroid, anti-TNF, or anti-α4β7 therapies. High expression of both IL7R and IL-7R signaling signature in the colon before treatment is strongly associated with nonresponsiveness to anti-TNF therapy. While in mice IL-7 is known to play a role in systemic inflammation, we found that in humans IL-7 also controlled α4β7 integrin expression and imprinted gut-homing specificity on T cells. IL-7R blockade reduced human T cell homing to the gut and colonic inflammation in vivo in humanized mouse models, and altered effector T cells in colon explants from UC patients grown ex vivo. Our findings show that failure of current treatments for CD and UC is strongly associated with an overexpressed IL-7R signaling pathway and point to IL-7R as a relevant therapeutic target and potential biomarker to fill an unmet need in clinical IBD detection and treatment.
Collapse
Affiliation(s)
| | - Richard Danger
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | - Laetitia Kermarrec
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France
| | - Véronique Nerrière-Daguin
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | | | - Tony Durand
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France
| | | | | | | | - Aneta Kucik
- Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom
| | | | - Jerome C Martin
- Precision Immunology Institute.,Tisch Cancer Institute.,Department of Oncological Sciences
| | - Christie Chang
- Precision Immunology Institute.,Tisch Cancer Institute.,Department of Oncological Sciences
| | - Adeeb Rahman
- Precision Immunology Institute.,Charles Bronfman Institute for Personalized Medicine, and.,Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Nina Salabert-Le Guen
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,CHU Nantes, Laboratoire d'Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), Nantes, France.,LabEx Immunograft Oncology (IGO), Nantes, France.,Université de Nantes, Faculté de Médecine, Nantes, France
| | - Cécile Braudeau
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,CHU Nantes, Laboratoire d'Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), Nantes, France.,LabEx Immunograft Oncology (IGO), Nantes, France
| | - Ahmed Abidi
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Université de Tunis El Manar, Laboratoire de génétique, immunologie et pathologies humaines, Faculté des sciences de Tunis, Tunis, Tunisia
| | - Grégoire David
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France
| | - Florent Malard
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France
| | - Celine Takoudju
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France
| | - Bernard Martinet
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | - Nathalie Gérard
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | - Isabelle Neveu
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France.,CHU Nantes, IMAD, Nantes, France
| | - Michel Neunlist
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France.,CHU Nantes, IMAD, Nantes, France
| | - Emmanuel Coron
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France.,CHU Nantes, IMAD, Nantes, France
| | - Thomas T MacDonald
- Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom
| | - Pierre Desreumaux
- Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille 2, Lille, France
| | - Hoa-Le Mai
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | - Stephanie Le Bas-Bernardet
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | - Jean-François Mosnier
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,CHU Nantes, Service d'Anatomie et Cytologie Pathologiques, Nantes, France
| | - Miriam Merad
- Precision Immunology Institute.,Tisch Cancer Institute.,Department of Oncological Sciences.,Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Régis Josien
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France.,CHU Nantes, Laboratoire d'Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), Nantes, France.,Université de Nantes, Faculté de Médecine, Nantes, France
| | - Sophie Brouard
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | - Jean-Paul Soulillou
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France
| | - Gilles Blancho
- Centre de Recherche en Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes (CHU Nantes), Nantes, France
| | - Arnaud Bourreille
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France.,CHU Nantes, IMAD, Nantes, France
| | - Philippe Naveilhan
- Institut des Maladies de l'Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France.,CHU Nantes, IMAD, Nantes, France
| | | | | |
Collapse
|
22
|
Menu E, Mary C, Toga I, Raoult D, Ranque S, Bittar F. A hospital qPCR-based survey of 10 gastrointestinal parasites in routine diagnostic screening, Marseille, France. Epidemiol Infect 2019; 147:e100. [PMID: 30869032 PMCID: PMC6518462 DOI: 10.1017/s0950268819000165] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Revised: 01/15/2019] [Accepted: 01/19/2019] [Indexed: 12/15/2022] Open
Abstract
There is a scarcity of recent epidemiological data on intestinal parasitic infections in France. We conducted a prospective study aimed at estimating the prevalence of 10 enteric parasites in Marseille, France, using real-time polymerase chain reaction (PCR)-based diagnosis. A total of 643 faeces from 488 patients referred to the Parasitology-Mycology Laboratory of the University Hospital of Marseille over a 6 months period were included. DNA was extracted using a semi-automated method. Parasites of interest were detected using singleplex quantitative PCRs (qPCRs). For positive samples, the Blastocystis subtype was determined by sequence analysis. During the study, the overall prevalence of enteric parasites was 17%. Blastocystis sp. was the most frequent species (10.5%), followed by Dientamoeba fragilis (2.3%) and Giardia intestinalis (2.3%). The prevalence of other parasites was <1% each. The ST3 Blastocystis subtype was predominant (43.6%) and the other subtypes identified were ST1, ST2, ST4 and ST6. This is the first time that a qPCR-based diagnosis has been used to survey the prevalence of 10 enteric parasites in a French University Hospital. This study confirms that fast, specific, sensitive and simultaneous detection in a single stool sample by qPCR clearly outperforms conventional microscopy-based diagnosis. Furthermore, qPCR is particularly well suited to surveying gastroenteritis agents.
Collapse
Affiliation(s)
- E. Menu
- Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
| | - C. Mary
- Aix Marseille University, IRD, APHM, VITROME, IHU-Méditerranée Infection, Marseille, France
| | - I. Toga
- Aix Marseille University, IRD, APHM, VITROME, IHU-Méditerranée Infection, Marseille, France
| | - D. Raoult
- Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
| | - S. Ranque
- Aix Marseille University, IRD, APHM, VITROME, IHU-Méditerranée Infection, Marseille, France
| | - F. Bittar
- Aix Marseille University, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France
| |
Collapse
|
23
|
Belarif L, Mary C, Jacquemont L, Mai HL, Danger R, Hervouet J, Minault D, Thepenier V, Nerrière-Daguin V, Nguyen E, Pengam S, Largy E, Delobel A, Martinet B, Le Bas-Bernardet S, Brouard S, Soulillou JP, Degauque N, Blancho G, Vanhove B, Poirier N. IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates. Nat Commun 2018; 9:4483. [PMID: 30367166 PMCID: PMC6203796 DOI: 10.1038/s41467-018-06804-y] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 09/26/2018] [Indexed: 01/01/2023] Open
Abstract
Targeting the expansion of pathogenic memory immune cells is a promising therapeutic strategy to prevent chronic autoimmune attacks. Here we investigate the therapeutic efficacy and mechanism of new anti-human IL-7Rα monoclonal antibodies (mAb) in non-human primates and show that, depending on the target epitope, a single injection of antagonistic anti-IL-7Rα mAbs induces a long-term control of skin inflammation despite repeated antigen challenges in presensitized monkeys. No modification in T cell numbers, phenotype, function or metabolism is observed in the peripheral blood or in response to polyclonal stimulation ex vivo. However, long-term in vivo hyporesponsiveness is associated with a significant decrease in the frequency of antigen-specific T cells producing IFN-γ upon antigen restimulation ex vivo. These findings indicate that chronic antigen-specific memory T cell responses can be controlled by anti-IL-7Rα mAbs, promoting and maintaining remission in T-cell mediated chronic inflammatory diseases.
Collapse
Affiliation(s)
- Lyssia Belarif
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,OSE Immunotherapeutics, Nantes, 44200, France
| | - Caroline Mary
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,OSE Immunotherapeutics, Nantes, 44200, France
| | - Lola Jacquemont
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Hoa Le Mai
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Richard Danger
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Jeremy Hervouet
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - David Minault
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Virginie Thepenier
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,OSE Immunotherapeutics, Nantes, 44200, France
| | - Veronique Nerrière-Daguin
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Elisabeth Nguyen
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Sabrina Pengam
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,OSE Immunotherapeutics, Nantes, 44200, France
| | - Eric Largy
- Quality Assistance, Thuin, 6536, Belgium.,ARNA laboratory, Université de Bordeaux, INSERM U1212, CNRS UMR5320, IECB, Bordeaux, 33076, France
| | | | - Bernard Martinet
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Stéphanie Le Bas-Bernardet
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, 44093, France
| | - Sophie Brouard
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, 44093, France
| | - Jean-Paul Soulillou
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France
| | - Nicolas Degauque
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, 44093, France
| | - Gilles Blancho
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, 44093, France
| | - Bernard Vanhove
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France.,OSE Immunotherapeutics, Nantes, 44200, France
| | - Nicolas Poirier
- Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes, 44093, France. .,OSE Immunotherapeutics, Nantes, 44200, France.
| |
Collapse
|
24
|
Watkins BK, Tkachev V, Furlan SN, Hunt DJ, Betz K, Yu A, Brown M, Poirier N, Zheng HB, Taraseviciute A, Colonna L, Mary C, Blancho G, Soulillou JP, Panoskaltsis-Mortari A, Sharma P, Garcia A, Strobert E, Hamby K, Garrett A, Deane T, Blazar BR, Vanhove B, Kean LS. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates. J Clin Invest 2018; 128:3991-4007. [PMID: 30102255 DOI: 10.1172/jci98793] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 06/26/2018] [Indexed: 12/30/2022] Open
Abstract
Controlling graft-versus-host disease (GVHD) remains a major unmet need in stem cell transplantation, and new, targeted therapies are being actively developed. CD28-CD80/86 costimulation blockade represents a promising strategy, but targeting CD80/CD86 with CTLA4-Ig may be associated with undesired blockade of coinhibitory pathways. In contrast, targeted blockade of CD28 exclusively inhibits T cell costimulation and may more potently prevent GVHD. Here, we investigated FR104, an antagonistic CD28-specific pegylated-Fab', in the nonhuman primate (NHP) GVHD model and completed a multiparameter interrogation comparing it with CTLA4-Ig, with and without sirolimus, including clinical, histopathologic, flow cytometric, and transcriptomic analyses. We document that FR104 monoprophylaxis and combined prophylaxis with FR104/sirolimus led to enhanced control of effector T cell proliferation and activation compared with the use of CTLA4-Ig or CTLA4-Ig/sirolimus. Importantly, FR104/sirolimus did not lead to a beneficial impact on Treg reconstitution or homeostasis, consistent with control of conventional T cell activation and IL-2 production needed to support Tregs. While FR104/sirolimus had a salutary effect on GVHD-free survival, overall survival was not improved, due to death in the absence of GVHD in several FR104/sirolimus recipients in the setting of sepsis and a paralyzed INF-γ response. These results therefore suggest that effectively deploying CD28 in the clinic will require close scrutiny of both the benefits and risks of extensively abrogating conventional T cell activation after transplant.
Collapse
Affiliation(s)
- Benjamin K Watkins
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Victor Tkachev
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Scott N Furlan
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Daniel J Hunt
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Kayla Betz
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Alison Yu
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Melanie Brown
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Nicolas Poirier
- Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France.,OSE Immunotherapeutics, Nantes, France
| | - Hengqi Betty Zheng
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Agne Taraseviciute
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Lucrezia Colonna
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Caroline Mary
- Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France.,OSE Immunotherapeutics, Nantes, France
| | - Gilles Blancho
- Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France
| | - Jean-Paul Soulillou
- Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France
| | - Angela Panoskaltsis-Mortari
- Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
| | - Prachi Sharma
- Yerkes National Primate Research Center, Atlanta, Georgia, USA
| | | | | | - Kelly Hamby
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Aneesah Garrett
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Taylor Deane
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA
| | - Bruce R Blazar
- Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA
| | - Bernard Vanhove
- Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire (CHU) Nantes, Nantes, France.,OSE Immunotherapeutics, Nantes, France
| | - Leslie S Kean
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute; The University of Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| |
Collapse
|
25
|
Besançon A, Goncalves T, Valette F, Mary C, Vanhove B, Chatenoud L, You S. A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice. Diabetologia 2018; 61:1811-1816. [PMID: 29845333 DOI: 10.1007/s00125-018-4638-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Accepted: 04/19/2018] [Indexed: 01/05/2023]
Abstract
AIMS/HYPOTHESIS The CD28/B7 interaction is critical for both effector T cell activation and forkhead box P3 (FOXP3)+ regulatory T cell (Treg) generation and homeostasis, which complicates the therapeutic use of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-immunoglobulin fusion protein (CTLA-4Ig) in autoimmunity. Here, we evaluated the impact of a simultaneous and selective blockade of the CD28 and mammalian target of rapamycin (mTOR) pathways in the NOD mouse model of type 1 diabetes. METHODS NOD mice were treated with PEGylated anti-CD28 Fab' antibody fragments (PV1-polyethylene glycol [PEG], 10 mg/kg i.p., twice weekly), rapamycin (1 mg/kg i.p., twice weekly) or a combination of both drugs. Diabetes incidence, pancreatic islet infiltration and autoreactive T cell responses were analysed. RESULTS We report that 4 week administration of PV1-PEG combined with rapamycin effectively controlled the progression of autoimmune diabetes in NOD mice at 10 weeks of age by reducing T cell activation and migration into the pancreas. Treatment with rapamycin alone was without effect, as was PV1-PEG monotherapy initiated at 4, 6 or 10 weeks of age. Prolonged PV1-PEG administration (for 10 weeks) accelerated diabetes development associated with impaired peripheral Treg homeostasis. This effect was not observed with the combined treatment. CONCLUSIONS/INTERPRETATION CD28 antagonist and rapamycin treatment act in a complementary manner to limit T cell activation and infiltration of pancreatic islets and diabetes development. These data provide new perspectives for the treatment of autoimmune diabetes and support the therapeutic potential of protocols combining antagonists of CD28 (presently in clinical development) and the mTOR pathway.
Collapse
Affiliation(s)
- Alix Besançon
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- INSERM U1151, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
- CNRS UMR 8253, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
| | - Tania Goncalves
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- INSERM U1151, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
- CNRS UMR 8253, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
| | - Fabrice Valette
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- INSERM U1151, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
- CNRS UMR 8253, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
| | | | - Bernard Vanhove
- OSE Immunotherapeutics, Nantes, France
- Inserm UMR-1064, Institut de Transplantation Urologie Néphrologie (ITUN), Nantes, France
| | - Lucienne Chatenoud
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- INSERM U1151, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
- CNRS UMR 8253, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
| | - Sylvaine You
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
- INSERM U1151, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
- CNRS UMR 8253, Institut Necker-Enfants Malades, Hôpital Necker, Paris, France
- Inserm U1016, Institut Cochin, Bâtiment Cassini, 123 Bd de Port Royal, 75014, Paris, France.
| |
Collapse
|
26
|
Laurent L, Le Fur A, Le Bloas R, Néel M, Mary C, Moreau A, Poirier N, Vanhove B, Fakhouri F. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28. Eur J Immunol 2017. [DOI: 10.1002/eji.201746923] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Laetitia Laurent
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
| | - Awena Le Fur
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- Department of nephrology and immunology; Centre Hospitalier Universitaire; Nantes France
| | - Rozenn Le Bloas
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
| | - Mélanie Néel
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
| | - Caroline Mary
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- OSE Immunotherapeutics; Nantes France
| | - Anne Moreau
- Department of pathology; Centre Hospitalier Universitaire; Nantes France
| | - Nicolas Poirier
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- OSE Immunotherapeutics; Nantes France
| | - Bernard Vanhove
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- OSE Immunotherapeutics; Nantes France
| | - Fadi Fakhouri
- INSERM UMR 1064; Nantes France
- Institut de Transplantation Urologie Néphrologie (ITUN); Université de Nantes; Nantes France
- Department of nephrology and immunology; Centre Hospitalier Universitaire; Nantes France
| |
Collapse
|
27
|
Poirier N, Blancho G, Hiance M, Mary C, Van Assche T, Lempoels J, Ramael S, Wang W, Thepenier V, Braudeau C, Salabert N, Josien R, Anderson I, Gourley I, Soulillou JP, Coquoz D, Vanhove B. First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28. J Immunol 2016; 197:4593-4602. [PMID: 27849166 DOI: 10.4049/jimmunol.1601538] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Accepted: 10/13/2016] [Indexed: 01/03/2023]
Abstract
FR104 is a monovalent pegylated Fab' Ab, antagonist of CD28, under development for treatment of transplant rejection and autoimmune diseases. In contrast to CD80/86 antagonists (CTLA4-Ig), FR104 selectively blunts CD28 costimulation while sparing CTLA-4 and PD-L1 coinhibitory signals. In the present work, FR104 has been evaluated in a first-in-human study to evaluate the safety, pharmacokinetics, pharmacodynamics, and potency of i.v. administrations in healthy subjects. Sixty-four subjects were randomly assigned to four single ascending dose groups, two double dose groups and four single ascending dose groups challenged with keyhole limpet hemocyanin. Subjects were followed up over a maximum of 113 d. Overall, the pharmacokinetics of FR104 after a single and double infusions was approximately linear at doses ≥0.200 mg/kg. CD28 receptor occupancy by FR104 was saturated at the first sampling time point (0.5 h) at doses above 0.02 mg/kg and returned to 50% in a dose-dependent manner, by day 15 (0.020 mg/kg) to 85 (1.500 mg/kg). FR104 was well tolerated, with no evidence of cytokine-release syndrome and no impact on blood lymphocyte subsets. Inhibition of anti-keyhole limpet hemocyanin Ab response was dose-dependent in FR104 recipients and was already apparent at a dose of 0.02 mg/kg. Abs to FR104 were detected in 22/46 (48%) of FR104 recipients and only 1/46 (2.2%) was detected during drug exposure. In conclusion, selective blockade of CD28 with FR104 was safe and well tolerated at the doses tested. The observed immunosuppressive activity indicated that FR104 has potential to show clinical activity in the treatment of immune-mediated diseases.
Collapse
Affiliation(s)
- Nicolas Poirier
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,OSE Immunotherapeutics S.A., Nantes F44200, France
| | - Gilles Blancho
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,Centre Hospitalier Universitaire Nantes, Laboratoire d'Immunologie, Centre d'immunomonitorage Nantes-Atlantique, Nantes, F44000, France
| | | | - Caroline Mary
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,OSE Immunotherapeutics S.A., Nantes F44200, France
| | - Tim Van Assche
- SGS Life Science Services, Clinical Pharmacology Unit Antwerp, Antwerp 2060, Belgium
| | - Jos Lempoels
- SGS Life Science Services, Clinical Pharmacology Unit Antwerp, Antwerp 2060, Belgium
| | - Steven Ramael
- SGS Life Science Services, Clinical Pharmacology Unit Antwerp, Antwerp 2060, Belgium
| | - Weirong Wang
- Janssen Research & Development, LLC, Spring House, PA 19477
| | - Virginie Thepenier
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,OSE Immunotherapeutics S.A., Nantes F44200, France
| | - Cecile Braudeau
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,LabEx ImmunoGraft Oncology, Nantes F44000, Nantes, France; and
| | - Nina Salabert
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,Centre Hospitalier Universitaire Nantes, Laboratoire d'Immunologie, Centre d'immunomonitorage Nantes-Atlantique, Nantes, F44000, France.,LabEx ImmunoGraft Oncology, Nantes F44000, Nantes, France; and
| | - Regis Josien
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,Centre Hospitalier Universitaire Nantes, Laboratoire d'Immunologie, Centre d'immunomonitorage Nantes-Atlantique, Nantes, F44000, France.,LabEx ImmunoGraft Oncology, Nantes F44000, Nantes, France; and
| | - Ian Anderson
- Janssen Research & Development, LLC, Spring House, PA 19477
| | - Ian Gourley
- Janssen Research & Development, LLC, Spring House, PA 19477
| | - Jean-Paul Soulillou
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France.,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France
| | | | - Bernard Vanhove
- Institut National de la Santé et de la Recherche Médicale UMR 1064, Nantes F44093, France; .,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire, Université de Nantes, Nantes F44000, France.,OSE Immunotherapeutics S.A., Nantes F44200, France.,LabEx ImmunoGraft Oncology, Nantes F44000, Nantes, France; and
| |
Collapse
|
28
|
Ville S, Poirier N, Branchereau J, Charpy V, Pengam S, Nerriere-Daguin V, Le Bas-Bernardet S, Coulon F, Mary C, Chenouard A, Hervouet J, Minault D, Nedellec S, Renaudin K, Vanhove B, Blancho G. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection. J Am Soc Nephrol 2016; 27:3577-3588. [PMID: 27160407 DOI: 10.1681/asn.2015070774] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Accepted: 03/17/2016] [Indexed: 12/18/2022] Open
Abstract
Belatacept is a biologic that targets CD80/86 and prevents its interaction with CD28 and its alternative ligand, cytotoxic T lymphocyte antigen 4 (CTLA-4). Clinical experience in kidney transplantation has revealed a high incidence of rejection with belatacept, especially with intensive regimens, suggesting that blocking CTLA-4 is deleterious. We performed a head to head assessment of FR104 (n=5), a selective pegylated Fab' antibody fragment antagonist of CD28 that does not block the CTLA-4 pathway, and belatacept (n=5) in kidney allotransplantation in baboons. The biologics were supplemented with an initial 1-month treatment with low-dose tacrolimus. In cases of acute rejection, animals also received steroids. In the belatacept group, four of five recipients developed severe, steroid-resistant acute cellular rejection, whereas FR104-treated animals did not. Assessment of regulatory T cell-specific demethylated region methylation status in 1-month biopsy samples revealed a nonsignificant trend for higher regulatory T cell frequencies in FR104-treated animals. Transcriptional analysis did not reveal significant differences in Th17 cytokines but did reveal higher levels of IL-21, the main cytokine secreted by CD4 T follicular helper (Tfh) cells, in belatacept-treated animals. In vitro, FR104 controlled the proliferative response of human preexisting Tfh cells more efficiently than belatacept. In mice, selective CD28 blockade also controlled Tfh memory cell responses to KLH stimulation more efficiently than CD80/86 blockade. Our data reveal that selective CD28 blockade and belatacept exert different effects on mechanisms of renal allograft rejection, particularly at the level of Tfh cell stimulation.
Collapse
Affiliation(s)
- Simon Ville
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| | - Nicolas Poirier
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France; and
| | - Julien Branchereau
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| | | | - Sabrina Pengam
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France; and
| | - Véronique Nerriere-Daguin
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | - Stéphanie Le Bas-Bernardet
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | - Flora Coulon
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | - Caroline Mary
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France; and
| | - Alexis Chenouard
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| | - Jeremy Hervouet
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | - David Minault
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | - Steven Nedellec
- MicroPiCell Facility, Structure Fédérative de Recherche (SFR) Bonamy, Structure Fedérative de recherche (FED) 4203, Unité Mixte de Service (UMS) 016, Nantes, France
| | - Karine Renaudin
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| | - Bernard Vanhove
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France; and
| | - Gilles Blancho
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1064, Nantes, France; .,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| |
Collapse
|
29
|
Poirier N, Chevalier M, Mary C, Hervouet J, Minault D, Le Bas-Bernardet S, Belarif L, Daguin V, Cassagnau E, Vanhove B, Blancho G. Selective CD28 antagonist prevents Aldara-induced skin inflammation in non-human primates. Exp Dermatol 2016; 25:233-4. [PMID: 26513536 DOI: 10.1111/exd.12891] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2015] [Indexed: 11/27/2022]
Affiliation(s)
- Nicolas Poirier
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France
| | - Mélanie Chevalier
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| | - Caroline Mary
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France
| | - Jérémy Hervouet
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | - David Minault
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | - Stéphanie Le Bas-Bernardet
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| | - Lyssia Belarif
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France
| | - Veronique Daguin
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France
| | | | - Bernard Vanhove
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Effimune, Nantes, France
| | - Gilles Blancho
- INSERM UMR 1064, Nantes, France.,Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France.,Centre Hospitalier Universitaire, Nantes, France
| |
Collapse
|
30
|
Vierboom MPM, Breedveld E, Kap YS, Mary C, Poirier N, 't Hart BA, Vanhove B. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clin Exp Immunol 2015; 183:405-18. [PMID: 26540618 DOI: 10.1111/cei.12739] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2015] [Indexed: 01/13/2023] Open
Abstract
T cells have a central pathogenic role in the aetiopathogenesis of rheumatoid arthritis (RA), and are therefore a favoured target of immunotherapy aiming at physical or functional elimination. Here we report an efficacy test of FR104, a new co-stimulation inhibitor directly targeting CD28 on T cells, in a translationally relevant model, the rhesus monkey model of collagen-induced arthritis (CIA). As a relevant comparator we used abatacept [cytotoxic T lymphocyte antigen immunoglobulin (CTLA Ig)], an antagonist of CTLA-4 binding to CD80/86 clinically approved for treatment of RA. Treatment with either compound was started at the day of CIA induction. Although FR104 previously demonstrated a higher control of T cell responses in vitro than abatacept, both compounds were equally potent in the suppression of CIA symptoms and biomarkers, such as the production of C-reactive protein (CRP) and interleukin (IL)-6 and anti-collagen type II (CII) serum antibody (IgM/IgG). However, in contrast to abatacept, FR104 showed effective suppression of CII-induced peripheral blood mononuclear cell (PBMC) proliferation. The current study demonstrates a strong potential of the new selective CD28 antagonist FR104 for treatment of RA.
Collapse
Affiliation(s)
- M P M Vierboom
- Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, the Netherlands
| | - E Breedveld
- Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, the Netherlands
| | - Y S Kap
- Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, the Netherlands
| | - C Mary
- Institut National De La Santé Et De La Recherche Médicale, Université De Nantes, Effimune SA, Nantes, France
| | - N Poirier
- Institut National De La Santé Et De La Recherche Médicale, Université De Nantes, Effimune SA, Nantes, France
| | - B A 't Hart
- Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, the Netherlands.,Department Neuroscience, University of Groningen, University Medical Center, Groningen, the Netherlands
| | - B Vanhove
- Institut National De La Santé Et De La Recherche Médicale, Université De Nantes, Effimune SA, Nantes, France
| |
Collapse
|
31
|
Le Govic Y, Guyot K, Certad G, Deschildre A, Novo R, Mary C, Sendid B, Viscogliosi E, Favennec L, Dei-Cas E, Fréalle E, Dutoit E. Assessment of microscopic and molecular tools for the diagnosis and follow-up of cryptosporidiosis in patients at risk. Eur J Clin Microbiol Infect Dis 2015; 35:137-48. [PMID: 26610340 DOI: 10.1007/s10096-015-2519-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 10/30/2015] [Indexed: 11/29/2022]
Abstract
Cryptosporidiosis is an important though underreported public health concern. Molecular tools might be helpful in improving its diagnosis. In this study, ZR Fecal DNA MiniPrep™ Kit (ZR) and NucliSens® easyMAG® (EM) were compared using four Cryptosporidium-seeded feces and 29 Cryptosporidium-positive stools. Thereafter, ZR was selected for prospective evaluation of Cryptosporidium detection by 18S rDNA and LAXER quantitative PCR (qPCR) in 69 stools from 56 patients after Cryptosporidium detection by glycerin, modified Ziehl-Neelsen (ZN) and auramine-phenol (AP) stainings. The combination of any of the two extraction methods with 18S qPCR yielded adequate detection of Cryptosporidium in seeded stools, but the ZR kit showed the best performance. All 29 Cryptosporidium-positive samples were positive with 18S qPCR, after both ZR and EM extraction. However, false-negative results were found with LAXER qPCR or nested PCR. Cryptosporidiosis was diagnosed in 7/56 patients. All the microscopic methods enabled the initial diagnosis, but Cryptosporidium was detected in 12, 13, and 14 samples from these seven patients after glycerin, ZN, and AP staining respectively. Among these samples, 14 and 12 were positive with 18S and LAXER qPCR respectively. In two patients, Cryptosporidium DNA loads were found to be correlated with clinical evolution. Although little known, glycerin is a sensitive method for the initial detection of Cryptosporidium. When combined with 18S qPCR, ZR extraction, which had not been evaluated so far for Cryptosporidium, was an accurate tool for detecting Cryptosporidium and estimating the oocyst shedding in the course of infection.
Collapse
Affiliation(s)
- Y Le Govic
- Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France.,Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire d'Angers, France; Groupe d'Etude des Interactions Hôte-Pathogène, UPRES-EA 3142, UNAM Université, Université d'Angers, Angers, France
| | - K Guyot
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - G Certad
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - A Deschildre
- Unité de pneumologie-allergologie pédiatrique, pôle enfant, clinique de pédiatrie Jeanne de Flandre, CHRU de Lille, Université de Lille, Lille, France
| | - R Novo
- Unité de Néphrologie Pédiatrique, CHRU de Lille, Lille, France
| | - C Mary
- Aix-Marseille Université, Faculté de Médecine, UMR MD3, et APHM, Laboratoire de Parasitologie-Mycologie, Hôpital de la Timone, Marseille, France
| | - B Sendid
- Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France.,Inserm U995, Université de Lille, Lille, France
| | - E Viscogliosi
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - L Favennec
- Laboratoire de Parasitologie, EA 3800-IRIB, CHRU de Rouen, Rouen, France
| | - E Dei-Cas
- Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France.,Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - E Fréalle
- Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France. .,Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.
| | - E Dutoit
- Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille, Université de Lille, Villeneuve-d'Ascq, France
| | | |
Collapse
|
32
|
Poirier N, Chevalier M, Mary C, Hervouet J, Minault D, Baker P, Ville S, Le Bas-Bernardet S, Dilek N, Belarif L, Cassagnau E, Scobie L, Blancho G, Vanhove B. Selective CD28 Antagonist Blunts Memory Immune Responses and Promotes Long-Term Control of Skin Inflammation in Nonhuman Primates. J Immunol 2015; 196:274-83. [PMID: 26597009 DOI: 10.4049/jimmunol.1501810] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Accepted: 10/28/2015] [Indexed: 11/19/2022]
Abstract
Novel therapies that specifically target activation and expansion of pathogenic immune cell subsets responsible for autoimmune attacks are needed to confer long-term remission. Pathogenic cells in autoimmunity include memory T lymphocytes that are long-lived and present rapid recall effector functions with reduced activation requirements. Whereas the CD28 costimulation pathway predominantly controls priming of naive T cells and hence generation of adaptive memory cells, the roles of CD28 costimulation on established memory T lymphocytes and the recall of memory responses remain controversial. In contrast to CD80/86 antagonists (CTLA4-Ig), selective CD28 antagonists blunt T cell costimulation while sparing CTLA-4 and PD-L1-dependent coinhibitory signals. Using a new selective CD28 antagonist, we showed that Ag-specific reactivation of human memory T lymphocytes was prevented. Selective CD28 blockade controlled both cellular and humoral memory recall in nonhuman primates and induced long-term Ag-specific unresponsiveness in a memory T cell-mediated inflammatory skin model. No modification of memory T lymphocytes subsets or numbers was observed in the periphery, and importantly no significant reactivation of quiescent viruses was noticed. These findings indicate that pathogenic memory T cell responses are controlled by both CD28 and CTLA-4/PD-L1 cosignals in vivo and that selectively targeting CD28 would help to promote remission of autoimmune diseases and control chronic inflammation.
Collapse
Affiliation(s)
- Nicolas Poirier
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Effimune, 44000 Nantes, France
| | - Melanie Chevalier
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Centre Hospitalier Universitaire, 44000 Nantes, France; and
| | - Caroline Mary
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Effimune, 44000 Nantes, France
| | - Jeremy Hervouet
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France
| | - David Minault
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France
| | - Paul Baker
- Department of Life Sciences, Glasgow Caledonian University, Glasgow G4 0BA, United Kingdom
| | - Simon Ville
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France
| | - Stephanie Le Bas-Bernardet
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Centre Hospitalier Universitaire, 44000 Nantes, France; and
| | - Nahzli Dilek
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Effimune, 44000 Nantes, France
| | - Lyssia Belarif
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Effimune, 44000 Nantes, France
| | | | - Linda Scobie
- Department of Life Sciences, Glasgow Caledonian University, Glasgow G4 0BA, United Kingdom
| | - Gilles Blancho
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Centre Hospitalier Universitaire, 44000 Nantes, France; and
| | - Bernard Vanhove
- INSERM UMR 1064, Institut de Transplantation Urologie Néphrologie, Université de Nantes, 44000 Nantes, France; Effimune, 44000 Nantes, France;
| |
Collapse
|
33
|
Haanstra KG, Dijkman K, Bashir N, Bauer J, Mary C, Poirier N, Baker P, Scobie L, 't Hart BA, Vanhove B. Correction: Selective Blockade of CD28-Mediated T Cell Costimulation Protects Rhesus Monkeys against Acute Fatal Experimental Autoimmune Encephalomyelitis. J Immunol 2015; 195:749. [PMID: 26138639 DOI: 10.4049/jimmunol.1501150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
34
|
Herisse A, Darles C, Mary C, Hubiche T, Del Giudice P, Chiaverini C, Lacour J, Tran A, Haas H, Loubatier C, Hasseine L, Marty P, Delaunay P. CO-37 – Place de la biologie moléculaire dans le diagnostic de gale. Arch Pediatr 2015. [DOI: 10.1016/s0929-693x(15)30139-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Haanstra KG, Dijkman K, Bashir N, Bauer J, Mary C, Poirier N, Baker P, Crossan CL, Scobie L, 't Hart BA, Vanhove B. Selective blockade of CD28-mediated T cell costimulation protects rhesus monkeys against acute fatal experimental autoimmune encephalomyelitis. J Immunol 2015; 194:1454-66. [PMID: 25589073 DOI: 10.4049/jimmunol.1402563] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Costimulatory and coinhibitory receptor-ligand pairs on T cells and APC control the immune response. We have investigated whether selective blockade of CD28-CD80/86 costimulatory interactions, which preserves the coinhibitory CTLA4-CD80/86 interactions and the function of regulatory T (Treg) cells, abrogates the induction of experimental autoimmune encephalomyelitis (EAE) in rhesus monkeys. EAE was induced by intracutaneous immunization with recombinant human myelin oligodendrocyte glycoprotein (rhMOG) in CFA on day 0. FR104 is a monovalent, PEGylated-humanized Fab' Ab fragment against human CD28, cross-reactive with rhesus monkey CD28. FR104 or placebo was administered on days 0, 7, 14, and 21. FR104 levels remained high until the end of the study (day 42). Placebo-treated animals all developed clinical EAE between days 12 and 27. FR104-treated animals did not develop clinical EAE and were sacrificed at the end of the study resulting in a significantly prolonged survival. FR104 treatment diminished T and B cell responses against rhMOG, significantly reduced CNS inflammation and prevented demyelination. The inflammatory profile in the cerebrospinal fluid and brain material was also strongly reduced. Recrudescence of latent virus was investigated in blood, spleen, and brain. No differences between groups were observed for the β-herpesvirus CMV and the polyomaviruses SV40 and SA12. Cross-sectional measurement of lymphocryptovirus, the rhesus monkey EBV, demonstrated elevated levels in the blood of FR104-treated animals. Blocking rhesus monkey CD28 with FR104 mitigated autoreactive T and B cell activation and prevented CNS pathology in the rhMOG/CFA EAE model in rhesus monkeys.
Collapse
Affiliation(s)
- Krista G Haanstra
- Biomedical Primate Research Centre, 2280 GH Rijswijk, the Netherlands;
| | - Karin Dijkman
- Biomedical Primate Research Centre, 2280 GH Rijswijk, the Netherlands
| | - Noun Bashir
- Biomedical Primate Research Centre, 2280 GH Rijswijk, the Netherlands
| | - Jan Bauer
- Center for Brain Research, Medical University of Vienna, 1090 Vienna, Austria
| | | | | | - Paul Baker
- Glasgow Caledonian University, Glasgow G4 0BA, United Kingdom
| | | | - Linda Scobie
- Glasgow Caledonian University, Glasgow G4 0BA, United Kingdom
| | - Bert A 't Hart
- Biomedical Primate Research Centre, 2280 GH Rijswijk, the Netherlands; University of Groningen, University Medical Center, Department of Neuroscience, 9713 GZ Groningen, the Netherlands; and
| | - Bernard Vanhove
- Effimune SAS, 44035 Nantes, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1064, 44093 Nantes, France
| |
Collapse
|
36
|
Poirier N, Dilek N, Mary C, Ville S, Coulon F, Branchereau J, Tillou X, Charpy V, Pengam S, Nerriere-Daguin V, Hervouet J, Minault D, Le Bas-Bernardet S, Renaudin K, Vanhove B, Blancho G. FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft. Am J Transplant 2015; 15:88-100. [PMID: 25488654 DOI: 10.1111/ajt.12964] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Revised: 08/01/2014] [Accepted: 08/04/2014] [Indexed: 01/25/2023]
Abstract
Selective targeting of CD28 might represent an effective immunomodulation strategy by preventing T cell costimulation, while favoring coinhibition since inhibitory signals transmitted through CTLA-4; PD-L1 and B7 would not be affected. We previously showed in vitro and in vivo that anti-CD28 antagonists suppress effector T cells while enhancing regulatory T cell (Treg) suppression and immune tolerance. Here, we evaluate FR104, a novel antagonist pegylated anti-CD28 Fab' antibody fragment, in nonhuman primate renal allotransplantation. FR104, in association with low doses of tacrolimus or with rapamycin in a steroid-free therapy, prevents acute rejection and alloantibody development and prolongs allograft survival. However, when FR104 was associated with mycophenolate mofetil and steroids, half of the recipients rejected their grafts prematurely. Finally, we observed an accumulation of Helios-negative Tregs in the blood and within the graft after FR104 therapy, confirmed by Treg-specific demethylated region DNA analysis. In conclusion, FR104 reinforces immunosuppression in calcineurin inhibitor (CNI)-low or CNI-free protocols, without the need of steroids. Accumulation of intragraft Tregs suggested the promotion of immunoregulatory mechanisms. Selective CD28 antagonists might become an alternative CNI-sparing strategy to B7 antagonists for kidney transplant recipients.
Collapse
Affiliation(s)
- N Poirier
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 1064, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), Université de Nantes, Nantes, France; Effimune SAS, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Mallet S, Mary C, De Sainte-Marie B, Bentaleb N, Gaudy-Marqueste C, Darles C, Richard MA, Grob JJ, Piarroux R. Intérêt de la technique de recherche des sarcoptes par PCR dans le diagnostic de la gale. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
38
|
Poirier N, Mary C, Le Bas-Bernardet S, Daguin V, Belarif L, Chevalier M, Hervouet J, Minault D, Ville S, Charpy V, Blancho G, Vanhove B. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28. MAbs 2014; 6:697-707. [PMID: 24598534 DOI: 10.4161/mabs.28375] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Antagonist anti-CD28 antibodies prevent T-cell costimulation and are functionally different from CTLA4Ig since they cannot block CTLA-4 and PDL-1 co-inhibitory signals. They demonstrated preclinical efficacy in suppressing effector T cells while enhancing immunoregulatory mechanisms. Because a severe cytokine release syndrome was observed during the Phase 1 study with the superagonist anti-CD28 TGN1412, development of other anti-CD28 antibodies requires careful preclinical evaluation to exclude any potential immunotoxicity side-effects. The failure to identify immunological toxicity of TGN1412 using macaques led us to investigate more relevant preclinical models. We report here that contrary to macaques, and like in man, all baboon CD4-positive T lymphocytes express CD28 in their effector memory cells compartment, a lymphocyte subtype that is the most prone to releasing cytokines after reactivation. Baboon lymphocytes are able to release pro-inflammatory cytokines in vitro in response to agonist or superagonist anti-CD28 antibodies. Furthermore, we compared the reactivity of human and baboon lymphocytes after transfer into non obese diabetic/severe combined immunodeficiency (NOD/SCID) interleukin-2rγ knockout mice and confirmed that both cell types could release inflammatory cytokines in situ after injection of agonistic anti-CD28 antibodies. In contrast, FR104, a monovalent antagonistic anti-CD28 antibody, did not elicit T cell activation in these assays, even in the presence of anti-drug antibodies. Infusion to baboons also resulted in an absence of cytokine release. In conclusion, the baboon represents a suitable species for preclinical immunotoxicity evaluation of anti-CD28 antibodies because their effector memory T cells do express CD28 and because cytokine release can be assessed in vitro and trans vivo.
Collapse
Affiliation(s)
- Nicolas Poirier
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France; Effimune SAS; Nantes, France
| | - Caroline Mary
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France; Effimune SAS; Nantes, France
| | - Stephanie Le Bas-Bernardet
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France; Centre Hospitalier Universitaire; Nantes, France
| | - Veronique Daguin
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France
| | - Lyssia Belarif
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France
| | - Melanie Chevalier
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France
| | - Jeremy Hervouet
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France
| | - David Minault
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France
| | - Simon Ville
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France
| | - Vianney Charpy
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France
| | - Gilles Blancho
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France; Centre Hospitalier Universitaire; Nantes, France
| | - Bernard Vanhove
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche; Institut de Transplantation Urologie Néphrologie (ITUN) ; Université de Nantes; Nantes, France; Effimune SAS; Nantes, France
| |
Collapse
|
39
|
Watkins BK, Poirier N, Mary C, Blancho G, Singh K, Garrett A, Hamby K, Deane T, Blazar BR, Vanhove B, Kean LS. Preventing Primate Gvhd Using a Novel Antagonistic Anti-CD28 Antibody Plus Rapamycin: Downregulation of CD8 Proliferation Predicts Gvhd-Free Survival. Biol Blood Marrow Transplant 2014. [DOI: 10.1016/j.bbmt.2013.12.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Dilek N, Poirier N, Hulin P, Coulon F, Mary C, Ville S, Vie H, Clémenceau B, Blancho G, Vanhove B. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One 2013; 8:e83139. [PMID: 24376655 PMCID: PMC3871694 DOI: 10.1371/journal.pone.0083139] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Accepted: 10/30/2013] [Indexed: 01/07/2023] Open
Abstract
CD28, CTLA-4 and PD-L1, the three identified ligands for CD80/86, are pivotal positive and negative costimulatory molecules that, among other functions, control T cell motility and formation of immune synapse between T cells and antigen-presenting cells (APCs). What remains incompletely understood is how CD28 leads to the activation of effector T cells (Teff) but inhibition of suppression by regulatory T cells (Tregs), while CTLA-4 and PD-L1 inhibit Teff function but are crucial for the suppressive function of Tregs. Using alloreactive human T cells and blocking antibodies, we show here by live cell dynamic microscopy that CD28, CTLA-4, and PD-L1 differentially control velocity, motility and immune synapse formation in activated Teff versus Tregs. Selectively antagonizing CD28 costimulation increased Treg dwell time with APCs and induced calcium mobilization which translated in increased Treg suppressive activity, in contrast with the dampening effect on Teff responses. The increase in Treg suppressive activity after CD28 blockade was also confirmed with polyclonal Tregs. Whereas CTLA-4 played a critical role in Teff by reversing TCR-induced STOP signals, it failed to affect motility in Tregs but was essential for formation of the Treg immune synapse. Furthermore, we identified a novel role for PD-L1-CD80 interactions in suppressing motility specifically in Tregs. Thus, our findings reveal that the three identified ligands of CD80/86, CD28, CTLA-4 and PD-L1, differentially control immune synapse formation and function of the human Teff and Treg cells analyzed here. Individually targeting CD28, CTLA-4 and PD-L1 might therefore represent a valuable therapeutic strategy to treat immune disorders where effector and regulatory T cell functions need to be differentially targeted.
Collapse
Affiliation(s)
- Nahzli Dilek
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France
| | - Nicolas Poirier
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France
| | - Philippe Hulin
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 892, Nantes, France
- Cellular and Tissular Imaging Core Facility (MicroPICell), Nantes, France
| | - Flora Coulon
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France
| | - Caroline Mary
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France
- Effimune S.A.S, Nantes, France
| | - Simon Ville
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France
| | - Henri Vie
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 892, Nantes, France
| | - Béatrice Clémenceau
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 892, Nantes, France
| | - Gilles Blancho
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France
- Centre Hospitalier Universitaire de Nantes, Institut de Transplantation Urologie Néphrologie, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
| | - Bernard Vanhove
- Institut National de la Santé Et de la Recherche Médicale, Unité mixte de Recherche 1064, Nantes, France
- Effimune S.A.S, Nantes, France
- Université de Nantes, Faculté de Médecine, Nantes, France
- * E-mail:
| |
Collapse
|
41
|
Faucher B, Bichaud L, Charrel R, Mary C, Izri A, de Lamballerie X, Piarroux R. Presence of sandflies infected with Leishmania infantum and Massilia virus in the Marseille urban area. Clin Microbiol Infect 2013; 20:O340-3. [PMID: 24107240 DOI: 10.1111/1469-0691.12404] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2013] [Accepted: 09/16/2013] [Indexed: 11/29/2022]
Abstract
Leishmaniasis is considered a rural disease in Europe. However, circumstantial evidence has indicated urban transmission of leishmaniasis and phleboviruses in the urban area of Marseille, France. To investigate this urban transmission, sandflies were trapped in 33 locations in the urban area (horse farms, public gardens and a residential area). Sandflies were always captured: 87.8% were Phlebotomus perniciosus, a vector of Leishmania infantum and Toscana and Massilia viruses. RT-PCR and cell culture inoculation identified the Massilia virus in 2/99 pools of sandflies, and PCR identified Leishmania in 5/99. No dual infection was observed, but both pathogens were detected in samples from the same trapping site.
Collapse
Affiliation(s)
- B Faucher
- Aix-Marseille University, UMR-MD3, Hôpital de La Timone, Marseille Cedex 5, France
| | | | | | | | | | | | | |
Collapse
|
42
|
Paugam A, L'Ollivier C, Viguié C, Anaya L, Mary C, de Ponfilly G, Ranque S. Comparison of real-time PCR with conventional methods to detect dermatophytes in samples from patients with suspected dermatophytosis. J Microbiol Methods 2013; 95:218-22. [DOI: 10.1016/j.mimet.2013.08.015] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2013] [Revised: 08/19/2013] [Accepted: 08/20/2013] [Indexed: 10/26/2022]
|
43
|
Mary C, Coulon F, Poirier N, Dilek N, Martinet B, Blancho G, Vanhove B. Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain. MAbs 2012; 5:47-55. [PMID: 23221503 DOI: 10.4161/mabs.22697] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Antagonist antibodies targeting CD28 have been proposed as an alternative to the use of CD80/86 antagonists to modulate T cell responses in autoimmunity and transplantation. Advantages would be the blockade of CD28-mediated co-stimulatory signals without impeding the co-inhibitory signals dependent on CD80 interactions with CTLA-4 and PD-L1 that are important for the control of immune responses and for the function of regulatory T cells. Anti-CD28 antibodies are candidate antagonists only if they prevent access to the CD80/86 ligands without simultaneously stimulating CD28 itself, a process that is believed to depend on receptor multimerization. In this study, we evaluated the impact of different formats of a potentially antagonist anti-human CD28 antibody on T cell activation. In particular, we examined the role of valency and of the presence of an Fc domain, two components that might affect receptor multimerization either directly or in the presence of accessory cells expressing Fc receptors. Among monovalent (Fab', scFv), divalent (Fab'2), monovalent-Fc (Fv-Fc) and divalent-Fc (IgG) formats, only the monovalent formats showed consistent absence of induced CD28 multimerization and absence of associated activation of phosphoinositol-3-kinase, and clear antagonist properties in T cell stimulation assays. In contrast, divalent antibodies showed agonist properties that resulted in cell proliferation and cytokine release in an Fc-independent manner. Conjugation of monovalent antibodies with polyethylene glycol, α-1-antitrypsin or an Fc domain significantly extended their in vivo half-life without modifying their antagonist properties. In conclusion, these data indicate that monovalency is mandatory for maintaining the antagonistic activity of anti-CD28 monoclonal antibodies.
Collapse
Affiliation(s)
- Caroline Mary
- Institut National de Santé Et de Recherche Médicale Unité Mixte de Recherche-Santé, Nantes, France
| | | | | | | | | | | | | |
Collapse
|
44
|
Poirier N, Dilek N, Mary C, Hervouet J, Minault D, Branchereau J, Tillou X, Le Bas-Bernardet S, Vanhove B, Blancho G. Evaluation of FR104, a Treg sparing antagonist anti-CD28 monovalent Fab’ antibody in kidney transplantation in non-human primates. J Transl Med 2012. [PMCID: PMC3508873 DOI: 10.1186/1479-5876-10-s3-p61] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
45
|
Mary C, Coulon F, Poirier N, Dilek N, Martinet B, Blancho G, Vanhove B. Antagonist properties of monoclonal antibodies to human CD28: role of valency and heavy-chain constant domain. Lab Invest 2012. [PMCID: PMC3509081 DOI: 10.1186/1479-5876-10-s3-p17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Caroline Mary
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-Santé 1064, Nantes, France,Effimune SAS, Nantes, France
| | - Flora Coulon
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-Santé 1064, Nantes, France
| | - Nicolas Poirier
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-Santé 1064, Nantes, France,Effimune SAS, Nantes, France
| | - Nahzli Dilek
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-Santé 1064, Nantes, France,Effimune SAS, Nantes, France
| | - Bernard Martinet
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-Santé 1064, Nantes, France
| | - Gilles Blancho
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-Santé 1064, Nantes, France,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire de Nantes, Université de Nantes, Nantes, France
| | - Bernard Vanhove
- Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche-Santé 1064, Nantes, France,Effimune SAS, Nantes, France,Institut de Transplantation Urologie Néphrologie, Centre Hospitalier Universitaire de Nantes, Université de Nantes, Nantes, France
| |
Collapse
|
46
|
Poirier N, Dilek N, Mary C, Vanhove B. Graft versus host disease in humanized mice is differentially controlled by CD28 and CD80/86 antagonists. Lab Invest 2012. [PMCID: PMC3508874 DOI: 10.1186/1479-5876-10-s3-o2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
47
|
Poirier N, Mary C, Dilek N, Hervouet J, Minault D, Blancho G, Vanhove B. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012; 12:2630-40. [PMID: 22759318 DOI: 10.1111/j.1600-6143.2012.04164.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Antagonist anti-CD28 antibodies prevent T cell costimulation and differentiate from CTLA4Ig since they cannot block CTLA-4 and PDL-1 coinhibitory signals. They demonstrated efficacy in suppressing effector T cells while enhancing regulatory T cells function and immune tolerance. However, anti-CD28 antibodies devoid of immunotoxicity and with a good pharmacokinetic profile have not yet been developed. Here, we describe FR104, a novel humanized pegylated anti-CD28 Fab' antibody fragment presenting a long elimination half-life in monkeys. In vitro, FR104 failed to induce human T cell proliferation and cytokines secretion, even in the presence of anti-CD3 antibodies or when cross-linked with secondary antibodies. Furthermore, in humanized NOD/SCID mice adoptively transferred with human PBMC, whereas superagonist and divalent antibodies elicited rapid cytokines secretion and human T cell activation, FR104 did not. These humanized mice developed a florid graft-versus-host disease, which was prevented by administration of FR104 in a CTLA4-dependent manner. Interestingly, administration of high doses of CTLA4-Ig was ineffective to prevent GVHD, whereas administration of low doses was partially effective. In conclusion, we demonstrated that FR104 is devoid of agonist activity on human T cells and thus compatible with a clinical development that might lead to higher therapeutic indexes, by sparing CTLA-4, as compared to CD80/CD86 antagonists.
Collapse
Affiliation(s)
- N Poirier
- Institut National de la Santé Et de la Recherche Médicale Unité Mixte de Recherche 1064, Nantes, France
| | | | | | | | | | | | | |
Collapse
|
48
|
Michel Nguyen A, Normand AC, Cassagne C, Ranque S, Piarroux R, Mary C. Candida palmioleophila , problèmes d’identification et sensibilité. J Mycol Med 2012. [DOI: 10.1016/j.mycmed.2011.12.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
49
|
Bichaud L, Piarroux R, Izri A, Ninove L, Mary C, De Lamballerie X, Charrel R. Low seroprevalence of sandfly fever Sicilian virus antibodies in humans, Marseille, France. Clin Microbiol Infect 2011; 17:1189-90. [DOI: 10.1111/j.1469-0691.2011.03509.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Faucher B, Pomares C, Gaudart J, Piarroux M, Faraut F, Mary C, Marty P, Piarroux R. Leishmaniose viscérale méditerranéenne : éco-épidemiologie urbaine en Provence. Rev Epidemiol Sante Publique 2010. [DOI: 10.1016/j.respe.2010.06.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|